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ABSTRACT 
 
To invade host erythrocytes, the malaria parasite, Plasmodium falciparum, produces 
invasion proteins, which are translocated through the secretory pathway by an N-terminal 
signal peptide. Additional motifs allow the proteins to be transported to the secretory 
organelles, the rhoptries and micronemes. Proteins of the Duffy Binding-Like Erythrocyte 
Binding Protein (DBL-EBP) family possess a C-terminal cysteine-rich domain, proposed 
to be the motif necessary for targeting. To investigate this hypothesis, mini-gene constructs 
were created from two DBL-EBPs, MAEBL and JESEBL by overlap extension PCR, and 
used to transfect 3D7 P. falciparum parasites. It was anticipated that only chimaeric 
proteins containing the domain would be correctly localized to the secretory organelles, 
while those without the domain would remain within the cytoplasm. Two constructs were 
produced for MAEBL, containing the signal peptide, transmembrane domain and 
cytoplasmic tail, with the C-terminal cysteine-rich domain either present, M1 (CCys), or 
absent, M2 (∆CCys). These were cloned into the pARL-GFP plasmid that had been 
modified by replacing the crt promoter with the ama-1 promoter for stage-specific 
expression. A third construct contained the JESEBL signal peptide and C-terminal 
cysteine-rich domain, J (CCys), which was cloned into the pARL-mCherry/ama-1 
promoter plasmid. Successfully transfected parasites were visible 25-30 days post-
transfection and the presence of the episomal plasmids was verified by PCR. Microscopic 
analysis of live parasites revealed diffuse fluorescence in the cytoplasmic regions for 
control transfectants carrying the empty pARL2-GFP and pARL-mCherry vectors, as 
expected. The chimaeric M2 (∆CCys) protein showed a similar pattern to the control GFP, 
however, chimaeric M1 (CCys) was localized to the parasite apex, indicating secretory 
organelle localization. These results showed that the C-terminal cysteine-rich domain is 
sufficient and necessary for apical trafficking of MAEBL. The chimaeric J (CCys) protein 
was localized throughout the cytoplasmic and apical regions, indicating partial trafficking 
of the protein to the secretory organelles. This was further confirmed by co-localization 
studies whereby EBA-175 was used as a micronemal marker. The JESEBL C-terminal 
cysteine-rich domain is therefore sufficient but not completely adequate for correct protein 
trafficking. Based on these data and other published studies, two hypothetical models are 
proposed for the transport of MAEBL and JESEBL to the apical organelles. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background of malaria infection 
The most severe form of human malaria is caused by the Plasmodium falciparum (P. 
falciparum) parasite. This parasite belongs to the phylum Apicomplexa as it possesses a set 
of membrane organelles known as the apical complex. The P. falciparum genome 
sequence was published in 2002 (Gardner et al., 2002), providing an expanse of 
information to aid further research into malaria infection. 
 
Malaria transmission occurs in regions across the equatorial belt, including South America, 
South-East Asia, the Western Pacific, the Eastern Mediterranean and most severely, sub-
Saharan Africa. Up to 3.5 billion people around the world (approximately half of the 
world’s population) are at risk of malaria infection, with ongoing malaria transmission 
occurring in 97 countries and territories. Latest reports published in December 2013 
showed approximately 207 million cases of malaria in 2012, and of this number, it is 
estimated that malaria claimed the lives of 627 000 people (World Malaria Report 2013, 
www.who.int). More than 90% of malaria deaths occur in Africa, where a child dies from 
malaria every minute.  
 
The spread of parasite resistance to anti-malaria medications, the lack of an effective 
vaccine, and the fragility of malaria control programmes have increased the need for new 
innovations in Plasmodium research.      
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1.2. P. falciparum life cycle 
The parasite lifecycle (reviewed in Cowman et al., 2012 & Cowman and Crabb, 2006) is 
complex, consisting of sexual and asexual stages (figure 1). The parasite is transmitted via 
the female Anopheles mosquito. When the mosquito takes a blood meal, parasites are 
injected into the human host in the form of sporozoites. The motile sporozoites travel to the 
liver, where they infect hepatocytes. Within the hepatocyte, the sporozoite develops and 
replicates to form thousands of merozoites. The non-motile merozoites are then released 
into the bloodstream, where they invade erythrocytes. Once within the erythrocyte, the 
merozoite develops and progresses through the ring, trophozoite and schizont stages, 
forming up to 32 daughter merozoites. As these daughter merozoites egress from the 
infected erythrocyte, they contact and invade more erythrocytes, causing high levels of 
infection and disease symptoms. A few of the intraerythrocytic parasites form male and 
female gametocytes. These are ingested by the mosquito and consequently develop into 
gametes which fuse to form a zygote within the insect’s gut. The zygote develops into an 
oocyst, where sporozoites are formed and released. These enter the salivary glands, 
allowing the parasite to be spread among human hosts. 
 
  
 
 
1.3. The intraerythrocytic life stage
The merozoite possesses the invasion machinery needed for host erythrocyte entry
(reviewed in Cowman et al.
a lemon in shape, with specialised secretory or
dense granules, found at the apical end, opposite a large nucleus 
figure 2). Proteins on the surface of the merozoite interact with receptors on the 
erythrocyte membrane. The merozoite then re
apical end of the merozoite and the erythrocyte 
Movement of this junction allows the merozoite to enter the erythrocyte, surrounded by
parasitophorous vacuole (PV).
 
Figure 1. The P. falciparum
and human host, including the asexual intraerythrocytic life stage is shown (Tham 
 
 
, 2012 & Cowman and Crabb, 2006). A merozoite is similar to 
ganelles, the rhoptries, micronemes and 
(Bannister 
-orientates to form a junction between the 
(Aikawa et al., 1978, Dvorak 
 
 life cycle. The transmission of the parasite between the 
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et al., 2000, 
et al., 1975). 
 a 
mosquito 
et al. 2012).  
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Proteins contained within the secretory organelles are released during merozoite invasion, 
to aid in attachment to the host cell, and development of the moving junction and PV. This 
process allows the invasion proteins to be secreted at the time of, or just before the 
merozoite attaches to the host erythrocyte. Adams et al. (1990) suggested that this rapid 
‘just in time’ process may aid in evasion of host immune detection, however, advanced 
imaging studies are still unable to elucidate the exact timing of the secretion of rhoptry or 
microneme contents (Hanssen et al., 2013). P. falciparum parasites are able to utilize 
various erythrocyte surface receptors, by virtue of the many redundant invasion proteins 
(Dolan et al., 1990). However, exact functions of many of these proteins are still widely 
unknown.  
 
 
 
Figure 2. The ultrastructure of a merozoite. The apical region containing the secretory 
organelles, the micronemes, rhoptries and dense granules is shown. The large nucleus is 
situated opposite to the apical region (Cowman & Crabb, 2006).  
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1.4. The erythrocyte binding proteins 
Plasmodium merozoites recognise and bind to receptors on the surface of host cell 
erythrocytes, including Duffy blood (DB) group antigens and sialic acids on surface 
glycophorins. Miller et al. (1975) were the first to observe the ability of Plasmodium spp 
(P. knowlesi and P. vivax) to utilize the DB group determinants for host erythrocyte 
invasion. The parasite-derived invasion proteins, which bind to these receptors, were 
identified and grouped as a family of DB proteins (DBPs) (Adams et al., 1990). The DBP 
domain responsible for binding was found to be an N-terminal cysteine-rich domain, which 
was named region II (Adams et al., 2001, Chitnis and Miller, 1994). 
 
A P. falciparum derived 175kDa antigen, now named erythrocyte binding antigen-175 
(EBA-175), utilizes sialic acid on erythrocyte glycophorins as a binding receptor (Camus 
and Hadley, 1985) in an essential invasion reaction (Sim et al., 1990). The region of the 
EBA-175 protein responsible for erythrocyte binding was a cysteine-rich domain, 
homologous to region II of the DBPs (Sim et al., 1994). Furthermore, Sim et al. (1994) 
elucidated the EBA-175 binding site as glycophorin A. 
 
Adams et al. (1992) deduced that the DBPs and sialic acid-binding EBA-175 belong to a 
gene family due to similarity in exon/intron gene structure and amino acid homology. The 
family was named the erythrocyte binding protein (EBP) family. Furthermore, multiple P. 
falciparum genes have been identified to have erythrocyte binding domains related to those 
of the EBP family, termed Duffy binding-like (DBL) domains (Peterson et al., 1995). 
Members of the DBL-EBP superfamily have multi-exon structures; conserved boundaries 
between exons and introns; a conserved N-terminal cysteine-rich domain (DBL domain) 
and a C-terminal cysteine-rich (CCys) domain (Adams et al., 1992, figure 3). Six dbl-ebp 
 genes have been identified in the 
1985), eba-140/baebl (Mayer 
al., 2001), ebl-1 (Peterson and Wellems, 2000
and the merozoite adhesive
These proteins contain tandem DBL domains named F1 and F2, with the exception of 
MAEBL which contains the M1/M2 b
BAEBL are well characterized while 
the encoded CCys of EBL
but the overall DBL-EBP characterist
 
 
 
 
 
P. falciparum is able to switch between invasion pathways 
1990), and different invasion proteins have been found to function
(Lopaticki et al., 2011). Therefore, 
the regulators which allow newly synthesized invasion proteins
Figure 3. Schematic representations of the 
to the P. vivax dbp based on amino acid homology and gene structure. Conserved domains 
(coloured blocks), exons (white blocks) and introns (solid lines) are indicated. 
proteins contain tandem DBL binding domains (F1/F2), with the exception of MAEBL (Adams 
al., 2001).  
P. falciparum genome, eba-175 (Camus and Hadley, 
et al., 2001, Thompson et al., 2001), ebl-165
), eba-181/jesebl (Gilberger 
 erythrocyte binding-like protein (maebl) (Kappe 
inding domain (see section 1.4.1). EBA
pebl is predicted to be a pseudogene. Furthermore, 
-1 contains only four of the eight conserved cysteine residues, 
ics are present.  
(Cortes, 2008
invasion proteins are not ideal drug targets. However, 
 to be trafficked to the 
P. falciparum dpb-ebp gene family. Genes are related 
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/pebl (Triglia et 
et al., 2003b), 
et al., 1998). 
-175 and 
 
, Dolan et al., 
 cooperatively 
P. falciparum 
et 
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secretory organelles, may be common between different invasion proteins. Therefore, it is 
important for new research to span this area of parasite biology. 
  
1.4.1. MAEBL 
MAEBL is expressed in both the sporozoite and the erythrocytic stages of the P. 
falciparum life cycle (Ghai et al., 2002). Maebl gene structure was first identified in the 
rodent parasites Plasmodium yoelii yoelii and Plasmodium berghei (Kappe et al., 1998) 
and has subsequently been shown to be conserved in Plasmodium species, including P. 
falciparum (Blair et al., 2002) and the avian parasite P. gallinaceum (Martinez et al., 
2013). Furthermore, maebl is conserved between P. falciparum strains (Blair et al., 2002).  
 
Maebl encodes a unique and complex transcript. Firstly, it is suspected to be a bicistronic 
message as the ~2kb 5’ untranslated region contains a multi-exon open reading frame 
predicted to encode a mitochondrial ATP-synthase subunit (gene ID PF11_0485) (Balu et 
al., 2009). Secondly, it has been found that two functional isoforms of maebl exist in 
sporozoite and erythrocytic stages, across Plasmodium species, due to alternative splicing 
of 3’ exons (Saenz et al., 2008, Singh et al., 2004).     
 
MAEBL plays a role in erythrocyte invasion, although the exact function is still unknown. 
However, the highly conserved manner in which maebl evolved indicates a possible role in 
initial interactions with the host erythrocyte (Michon et al., 2002). Fu et al. (2005) 
performed a targeted disruption of the maebl gene and proposed that MAEBL may be 
involved in the processing or control of other invasion-related proteins, or that it may be 
important when conditions are not optimal. The invasion mechanism utilized by MAEBL 
is both sialic acid-dependent and trypsin-insensitive, indicating a novel alternative pathway 
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dissimilar to those used by other invasion proteins (Fu et al., 2005). Preiser et al. (2004) 
further showed the importance of MAEBL in sporozoite infection of hepatocytes, as 
antibodies against various regions of MAEBL inhibited sporozoites from penetrating 
hepatocytes and therefore reduced the development of liver-stage parasites.  
 
MAEBL is a unique member of the DBL-EBP family in two ways. Firstly, MAEBL 
localizes within the rhoptry organelles, unlike other EBPs which localise to the 
micronemes (Blair et al., 2002). Secondly, maebl has an altered functional domain at the 
N-terminal. Instead of the DBL domain, MAEBL has tandem duplicate cysteine-rich 
regions M1 and M2 which are similar to the first two domains of a different parasite 
protein, Apical Membrane Antigen-1 (AMA-1) (Kappe et al., 1998). Phylogenetic analysis 
has shown that maebl evolved as an intact gene before the speciation of Plasmodium and is 
not a result of recombination between ama-1 and an ebp (Michon et al., 2002). However, 
MAEBL is homologous to DBL-EBPs in the CCys domain, which has an ancient origin in 
evolutionary history, indicating an important functional role (Michon et al., 2002).  
 
The Pfmaebl gene (PF3D7_1147800.1) is 6762bp long, consisting of five exons (figure 4). 
The coding sequence is 6168bp, encoding a 2056 amino acid (aa) predicted product (Blair 
et al., 2002). The Pf-MAEBL protein consists of six domains: (1) N-terminal signal 
peptide (SP); (2) the binding domain, M1 and M2; (3) repeat region; (4) CCys; (5) 
transmembrane domain (TM) and (6) cytoplasmic tail (CT) (Ghai et al., 2002). Other than 
the important function in host receptor binding, it has been suggested that residues within 
the M1 and M2 domains, which are highly conserved in AMA-1 domains I and II, may 
also infer a important role for the MAEBL protein structure  (Chesne-Seck et al., 2005). 
 The SP directs protein traffick
(Noe et al., 2000), while no roles have been reported for the repeat region or the CCys. 
 
 
 
 
 
1.4.2. JESEBL 
In 2003, an EBA-175 paralogue, termed EBA
al., 2003b). As is the case with EBA
Little is known about this protein or the receptor to which it binds, however, it is known to 
bind to the human erythrocyte membrane protein 4.1 (Lanzillotti and Coetzer, 2006). This 
interaction may aid in erythrocyte receptor binding or cause the erythrocyte cytoskeleton to 
become destabilized, thus assisting parasite invasion.
 
Figure 4. Schematic representations of 
amino acid and nucleotide sequence lengths are shown. Exons are represented with roma
numerals, introns are shown by black lines between exons and protein domains are indicated. 
Based on information obtained from Kappe 
ing through the Endoplasmic Reticulum (ER) and Golgi
 
-181 or JESEBL, was described
-175, JESEBL localizes to merozoite micronemes. 
 
maebl and jesebl gene and protein structures. Predicted 
et al. (1998) and Gilberger et al.
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 (Gilberger et 
n 
 (2003b).  
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The jesebl gene (PF3D7_0102500) is 5050bp long, comprising four exons, separated by 
three introns. The JESEBL protein is 1567aa long, consisting of five regions. The protein 
structure is very similar to MAEBL (figure 4), other than the two tandem DBL cysteine-
rich domains, termed F1 and F2, which are characteristic of DBL-EBPs (Gilberger et al., 
2003b). Polymorphisms within the F1/F2 binding domain have been found to change the 
level of erythrocyte receptor binding without changing the parasite invasion profile (Maier 
et al., 2009). These changes possibly alter the protein surface structure, thereby changing 
its binding affinity. Similar findings were recorded for JESEBL polymorphisms expressed 
in Brazilian patients (Lobo et al., 2004)   
 
JESEBL is an important invasion protein. A study of patients from Papua New Guinea 
showed that antibody responses to regions of JESEBL were strongly associated with 
protection from the development of symptomatic malaria (Richards et al., 2010). 
Furthermore, studies of South American field isolates pointed to JESEBL as a major player 
in erythrocyte invasion by P. falciparum parasites (Lopez-Perez et al., 2012, Villasis et al., 
2012).   
 
1.5. Protein trafficking 
P. falciparum parasites require complex transport mechanisms to sort proteins within 
cellular compartments (secretory organelles, food vacuole or apicoplast) and to export 
proteins to extracellular compartments such as the PV, the Maurer’s clefts or the host cell.  
 
1.5.1. Trafficking of P. falciparum proteins to the secretory organelles 
Eukaryotes synthesise secretory proteins from RNA molecules using ribosomes. The 
synthesised proteins are then translocated into the Golgi by means of an N-terminal signal 
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peptide. This is also true for many P. falciparum secretory proteins, including those of the 
DBL-EBP family. Once these proteins have passed through the ER and Golgi network, 
further targeting signals should direct translocation into the secretory organelles. However, 
recent reports agree that conserved motifs driving this mechanism are yet to be discovered 
(reviewed in Deponte et al., 2012). 
 
N-terminal motifs have been identified to be the trafficking determinants for various 
invasion proteins. Transfected parasites expressing chimaeric GFP-fusion proteins showed 
that only the first 20aa of the P. falciparum Armadilo Repeats-Only (ARO) protein 
(Cabrera et al., 2012) and the first 24aa of PfRhopH2 (Ghoneim et al., 2007) are required 
for rhoptry localization. An elegant study by Richard et al. (2009) gave a detailed account 
of the rhoptry trafficking signals for rhoptry associated protein 1 (RAP1). It was found that 
amino acids 22-55 were sufficient and necessary for targeting, refining previous studies 
that implicated the first 344 N-terminal amino acids in rhoptry localization (Baldi et al., 
2000). The site contained within the 22-55aa sequence was found to bind to the C-terminus 
of rhoptry associated membrane antigen (RAMA), using a pull-down assay.  RAMA acts 
as an escorter via association with lipid rafts (Topolska et al., 2004). The RAP1 rhoptry-
targeting signal was compared to other Plasmodium rhoptry proteins but the motif was not 
conserved (Richard et al., 2009).  
 
Motifs contained within the N-terminus are not the only trafficking determinants 
previously identified in Plasmodium. The thrombospondin-related anonymous protein 
(TRAP) contains a tyrosine motif in the CT which is important for sporozoite microneme 
localization in P. berghei (Bhanot et al., 2003). Similarly, a conserved acidic motif in the 
CT of Plasmodium reticulocyte binding protein-like (RBL) proteins may be important for 
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trafficking to rhoptries (DeSimone et al., 2009). The CT of merozoite surface sheddase 
PfSUB2 does not contribute to microneme trafficking, while the TM was found to be 
necessary for this role (Child et al., 2013). However, the CT was implicated in further 
translocation of PfSUB2 to the merozoite surface. Similarly, it has been found that the CT 
is not required for microneme trafficking of EBA-175, EBA-140, EBA-181 (Gilberger et 
al., 2003a, Treeck et al., 2006) or AMA-1 (Treeck et al., 2009).  
 
The dispensability of the CT for these various Plasmodium invasion proteins leads one to 
question whether they need to interact with escorter proteins which contain the required 
CT signal, to interact with the trafficking machinery. A cargo receptor protein fulfilling 
this function has been identified in the closely related apicomplexan parasite Toxoplasma 
gondii (Sloves et al., 2012). It was found that the CT of this cargo protein, TgSORTLR, is 
essential for the apical trafficking of various microneme (MIC1 and MIC4) and rhoptry 
(ROP1, ROP2, ROP4 and ROP5) proteins. It was predicted that the TgSORTLR CT 
physically interacts with the MIC and ROP proteins in the Golgi compartment and then 
coordinates with cytosolic trafficking proteins such as clathrin, adaptor protein adaptins, 
Sec23/Sec24 and vacuolar sorting proteins Vsp9, Vps26 and Vsp35. 
 
1.6. The C-terminal cysteine-rich domain 
The CCys domain is highly conserved between members of the EBP family, across 
Plasmodium species (Adams et al., 1992, Kappe et al., 1997). The domain contains eight 
conserved cysteine residues. These residues are highlighted in the related proteins P. 
falciparum EBA-175 and P. yoelii EBL (figure 5).  
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The CCys, the SP, and accurate timing of expression are sufficient and necessary for 
trafficking EBA-175 from the Golgi and ER network to the appropriate destination, the 
micronemes (Treeck et al., 2006). A single amino acid change whereby the second 
cysteine residue within the CCys domain was substituted with arginine caused the P. yoelii 
EBL protein localization to change from the micronemes to the dense granules (Otsuki et 
al., 2009). A similar result has been shown for the same cysteine substitution and other 
amino acid substitutions in P. falciparum (Sakura et al., 2013), indicating the importance 
of individual residues in protein trafficking.   
 
Figure 6 shows the eight conserved cysteine residues in four P. falciparum DBL-EBP 
proteins, EBA-175, BAEBL, JESEBL and MAEBL. The homology between the CCys 
domains of these proteins leads to the possibility that this domain may be a conserved 
trafficking determinant for this protein family. To test this theory, the two candidates, 
MAEBL and JESEBL were chosen for evaluation. 
 
 
 
 
 
Pf  EBA-175 NK C ENEISVKY C DHMIHEEIPLKT C TKEKTRNL CC AVSDY C MSYFTYDSEEYYN C TKREFDDPSYT C FR
Py  EBL NM C TNDVSSKY C DYMKDKISSGN C SNDERKQL CC SISDY C LNYFDYNSNKYYD C TKKEFSDPLYK C FS
EBA-175 NK C ENEISVKY C DHMIHEEIPLKT C TKEKTRNL CC AVSDY C MSYFTYDSEEYYN C TKREFDDPSYT C FR
BAEBL NK C NNEYSMEY C TYSDERNSSPGP C SREERKKL CC QISDY C LKYFNFYSIEYYN C IKSEIKSPEYK C FK
JESEBL NT C SNEHSLKY C QYMERNKDLLET C SEDKRLHL CC EISDY C LKFFNPKSIEYFD C TQKEFDDPTYN C FR
MAEBL NM C NNDFSSKY C DYMKDNISSGT C SNEERKSL CC SISDF C LKYFDHNSNKYYD C TKIEFADPLYR C FK
Figure 6. Protein sequence alignment of the DBL-EBP family. The alignment of the CCys 
domains of the EBL proteins EBA-175, BAEBL (EBA-140), JESEBL and MAEBL show eight 
highly conserved cysteine amino acids (red). Sequence information was taken from PlasmoDB, 
gene IDs PF3D7_0731500, PF3D7_1301600, PF3D7_0102500 and PF3D7_1147800.1 
respectively).   
Figure 5. Protein sequence alignment of the EBP family. The alignment of the CCys domains 
of the P. falciparum (EBA-175) and P. yoelii (EBL) EBPs show eight highly conserved 
cysteine amino acids (red). Sequence information was taken from PlasmoDB, gene IDs 
PF3D7_0731500 and PY05977.  
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1.7. Aims of the project 
The aim of this project is to investigate the role of the CCys domain in trafficking of DBL-
EBPs. It is aimed to determine if the CCys is necessary for targeting MAEBL to the 
rhoptries and JESEBL to the micronemes of P. falciparum parasites. The specific 
objectives are as follows: 
• Culture 3D7 P. falciparum parasites. 
• Design primers and perform PCR and overlap-extension PCR to create chimaeric 
constructs. 
• Modify the pARL-GFP and pARL2-mCherry vectors by replacing the chloroquine 
resistance transporter (crt) promoter with the ama-1 promoter. 
• Subclone the chimaeric constructs into the pARL vectors. 
• Transfect 3D7 P. falciparum parasites with the chimaeric constructs so that they 
will express fluorescent GFP- and mCherry-fusion proteins. 
• Analyse the transfectants by fluorescence microscopy and co-localization studies to 
determine protein localization. 
 
This project will lay the foundations for future work in protein trafficking signals of DBP-
EBPs and aid in the identification of possible P. falciparum escorter proteins. 
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CHAPTER 2 
MATERIALS AND METHODS 
All commercial reagents and the compositions of non-commercial reagents are listed in 
appendix A and appendix B respectively. 
 
2.1. Culturing techniques 
2.1.1. Culture composition and maintenance     
Working stocks of P. falciparum (3D7) cultures were kept frozen under liquid nitrogen and 
thawed when needed. The parasites were cultured in a sterile hood as by the method 
originally defined by Trager and Jensen (1976), with adjustments. Cultures consisted of 
parasitized erythrocytes (pRBCs) and washed erythrocytes, kept at a haematocrit of 5%. 
Cultures were maintained at 37˚C in 25cm3 (small) or 75cm3 (medium) sterile culture 
flasks (Nunc, Denmark), in 5ml (small) or 20ml (medium) complete medium. Cultures 
were gassed with a mixture of 5.5% CO2, 2.75% O2 and 91.25% N2 (Afrox, South Africa) 
for 1 minute for small flasks and 3 minutes for medium flasks, and the lids were closed. 
Complete medium was changed daily and cultures were continually diluted with fresh 
erythrocytes to maintain a parasitaemia of less than 3% trophozoites and less than 6% 
rings. Smears were also prepared on a daily basis to allow visualization of the life stage, 
parasitaemia and general health of the parasite cultures.  
 
2.1.2. Washing and diluting erythrocytes 
Blood was collected from volunteers in 6ml acid citrate dextrose tubes (Becton Dickinson 
Biosciences, USA). These tubes were centrifuged at 1000 x g for 10 minutes at 4˚C 
(Eppendorf Centrifuge 5702R, Germany), allowing the blood to separate into three layers. 
In a sterile hood, the top plasma and buffy layers were aspirated, leaving only a layer of 
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erythrocytes in the tube. Two volumes of incomplete medium were added and the contents 
of the tube were mixed by inversion to wash the erythrocytes. Centrifugation was repeated 
(1000 x g/10 min/4˚C) and the top layer was aspirated. This wash was performed twice. 
The erythrocytes were then diluted in one volume of incomplete medium and stored at 4˚C 
for up to two weeks.  
 
2.1.3. Preparation of culture from frozen stocks 
Frozen stocks, contained in cryotubes (TPP, Switzerland), were removed from liquid 
nitrogen and defrosted at 37˚C. Under sterile conditions, the thawed cells were transferred 
to a 15ml centrifuge tube (Greiner bio-one, Germany). For every millilitre of cells, 0.1ml 
of 12% sodium chloride was slowly added while stirring. The tube was incubated at room 
temperature for 5 minutes before the addition of 9 volumes of 1.6% sodium chloride. The 
suspension was gently mixed and then centrifuged at 400 x g for 5 minutes at room 
temperature (Eppendorf Centrifuge 5702 R, Germany). After the supernatant was removed, 
the pellet was resuspended in 9 volumes of sodium chloride/glucose solution (Blomqvist, 
2008). Centrifugation was repeated and the pellet was made up to a volume of 0.75ml 
using freshly washed and diluted erythrocytes (approximately 500µl of 1:1 diluted 
erythrocytes). The cells were then transferred to a small culture flask and complete 
medium was added to make a total volume of 5ml. The medium was made up with 1% 
albumax, instead of the usual 0.5% albumax; the increased protein constituent of the 
medium aids in parasite growth. The flask was then gassed and incubated as in 2.1.1. 
Smears were prepared and medium was changed daily (using the ‘boosted albumax’ 
medium) until parasitaemia reached approximately 3%. At this point culturing was 
continued with medium containing the usual 0.5% albumax. 
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2.1.4. Freezing culture stocks 
Cultures high in the parasite ring stage (5% or more) were frozen to make stocks as 
described by Normark (2008). A 20ml culture was transferred to two 15ml centrifuge 
tubes, under sterile conditions, and centrifuged at 400 x g for 5 minutes at room 
temperature. After removal of the supernatant, the pellet was resuspended in freezing 
solution at a ratio of 1:1. The suspension was then mixed well and transferred to sterile 
cryotubes (TPP, Switzerland) (0.5 – 1.0 ml per tube). Tubes were incubated at room 
temperature for 5 minutes before storing in liquid nitrogen.   
 
2.1.5. Smear Preparation 
Smears were prepared on a daily basis. Flasks were tilted upward, allowing the culture 
medium to flow back and exposing the thin layer of erythrocytes at the bottom of the flask. 
A glass Pasteur pipette (Marienfeld, Germany) was then used to take up ± 10µl of 
erythrocytes by capillary action. These erythrocytes were transferred to a glass microscope 
slide (Lasec, South Africa) and smeared thinly using the back of a second glass slide. The 
smear was allowed to air dry inside the flow hood and then stained using the Rapidiff Stain 
Set (Clinical Sciences Diagnostics CC, South Africa). Slides were viewed at 1000X 
magnification under oil immersion (Zeiss Axiostar, Germany).    
 
2.1.6. Calculating parasitaemia 
2.1.6.1. Calculating parasitaemia manually 
The slides were viewed in five fields. In each field the percentage parasitaemia was 
estimated using the following calculation: 
% Parasitaemia =  	 
	 
  	 
 x 100 
The average of the five calculations was taken as the estimated parasitaemia in each case. 
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2.1.6.2. Calculating parasitaemia via Flow Cytometry 
The DNA-binding dye thiazole orange (TO) was used to measure parasitaemia by flow 
cytometry using the method described by Engelbrecht and Coetzer (2013). Sorenson’s 
phosphate buffer (0.9ml) was used to dilute 10µl of P. falciparum culture and TO was 
added to a final concentration of 1mM (0.1ml of 10mM stock in methanol) in a 1.5ml 
microcentrifuge tube (Eppendorf, Germany). The tube was incubated in the dark at room 
temperature for 20 minutes before the suspension was analysed using a Beckman Coulter 
Gallios flow cytometer (Beckman Coulter Inc., USA). To control for background, an 
identical procedure was carried out whereby P. falciparum culture was exchanged for 
uninfected erythrocytes. Excitation was by 488 nm blue laser and emission was measured 
at 525 ± 20 nm (FL1 channel, 545/40BP filter). Optical alignment was monitored with 
Beckman Coulter Flow Check fluorspheres (Beckman Coulter Inc., USA). Erythrocytes 
were gated on a forward- versus side-scatter dot plot and analysed on a FL1 integral (log) 
histogram, with regions for uninfected, ring-infected and trophozoite-infected erythrocytes 
delineated. Approximately 50 000 events in the erythrocyte gate were counted. Post-
acquisition analyses were performed with Beckman Coulter Kaluza (v1.1) software. 
 
2.1.7. Feeding and diluting stock cultures 
Cultures were diluted when smears revealed the percentage of trophozoites in the culture to 
be 3% or more. For cultures with lower parasitaemia, the medium was merely changed by 
tilting the flask up and aspirating the old medium with a glass Pasteur pipette and pump 
system. Freshly made complete medium was then added in the following volumes: 5ml for 
a small flask and 20ml for a medium flask. To dilute 5ml cultures in 1:2, 1:5 or 1:10 ratios, 
2.5ml, 1ml or 0.5ml respectively of the culture was transferred to a sterile flask. Washed 
and diluted erythrocytes (see section 2.1.2) were then added to maintain a haematocrit of 
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5% in the new culture (250µl, 400µl and 450µl respectively) and complete medium was 
added to make a final volume of 5ml. Flasks were then gassed and incubated as in 2.1.1.  
 
2.1.8. Synchronisation of cultures 
High ring stage parasite cultures (5% or more) were synchronized using D-Sorbitol, as 
described by Lambros and Vanderberg (1979). Cultures (5ml) were transferred to sterile 
15ml centrifuge tubes and centrifuged at 1000 x g for 5 minutes at room temperature 
(Eppendorf Centrifuge 5702 R, Germany). The supernatant was aspirated and the pellet 
was resuspended in 10 volumes of 5% D-Sorbitol (approximately 2.5ml) and incubated for 
7-10 minutes at 37˚C. The sorbitol treatment causes lysis of the late-stage parasites 
(trophozoites and schizonts), leaving only the ring-stage parasites intact. The contents of 
the tube were mixed slowly by inversion before a second centrifugation. The supernatant 
was aspirated and the pellet was washed with complete medium. Washed and diluted 
erythrocytes (approximately 100µl) and complete medium (approximately 5ml) were 
added to the final erythrocyte pellet and the culture was returned to a flask and gassed as in 
2.1.1. Smears confirmed synchronisation of cultures.    
 
2.2. Preparation of nucleic acids 
2.2.1. RNA extraction 
Synchronised 5ml cultures containing ~5% late trophozoite to schizont stage parasites 
were used for RNA extraction. The experiment was carried out in sterile conditions and all 
instruments and surfaces were cleaned with RNaseZapTM (Ambion), to prevent RNase 
contamination. Cultures were transferred to sterile 15ml tubes and centrifuged at 1000 x g 
for 5 minutes at 4˚C (Eppendorf Centrifuge 5702 R, Germany). The supernatant was 
aspirated and the pellet was resuspended in 1980µl PBS and 20µl 5% saponin (final 
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concentration of 0.05% saponin). Incubation at room temperature for five minutes allowed 
erythrocytes to be lysed (Schlichtherle and Wahlgren, 2008). This was followed by a 
second centrifugation with the same conditions. The supernatant was aspirated and the 
pellet was washed with PBS until the supernatant was clear, resulting in a pellet composed 
of pure parasites.  
 
Total RNA was extracted from the parasites using Tri Reagent® (Sigma-Aldrich, USA), 
following the recommended protocol. TRI Reagent lyses parasites, releasing endogenous 
proteins and nucleic acids. Addition of chloroform and subsequent centrifugation separates 
the solution into three phases, a lower red organic phase containing the proteins, an upper 
colourless aqueous phase where the RNA is suspended, and a DNA interphase. It was then 
possible to precipitate and purify the RNA from the aqueous phase. The RNA pellet was 
dissolved in 20-30µl of nuclease-free water. Heating the sample to 60˚C for 15 minutes 
aided in this process. The concentration and purity of RNA was determined 
spectrophotometrically using a Nanodrop 1000 (Thermospecific, USA). An A260/A280 
value greater than 2 indicates pure RNA. RNA integrity was visualized by electrophoresis 
(as per section 2.3) and the solution was stored at -70˚C. 
 
2.3. Agarose Gel Electrophoresis 
Standard 1% agarose gels (50ml) were electrophoresed in 1X TAE buffer. By this method, 
DNA fragments may be separated based on size. RNA fragments were also separated in 
this way to check RNA integrity, however, size readings for RNA fragments were not 
accurate using this method. For visualization, 2.5µl of 10mg/ml ethidium bromide was 
added to a 50ml gel. This allows nucleic acid fragments to be seen under UV light using 
the Syngene gel doc and GeneSnap version 6.05 imaging software (Syngene, UK). For 
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every gel, 5µl of DNA ladder (MassRulerTM DNA Ladder Mix ready-to-use, Fermentas, 
Europe) was loaded into the first well, as a size standard. Loading dye (10X FastDigest® 
Green Buffer, Fermentas, Europe) was added to samples in a 1 dye: 5 sample ratio before 
loading into adjacent wells. The power source was set to provide maximum current at a 
voltage of 100V for electrophoresis. Current was applied for approximately 1 hour for 
adequate fragment separation. The concentrations of the separated products were 
calculated by Gene Tools imaging software (SynGene, UK). 
 
2.4. Plasmid preparation 
2.4.1. Preparation of the pARL2-GFP and pARL-mCherry plasmids for cloning 
The pARL2-GFP and pARL-mCherry plasmids were kindly provided by Dr Jude M. 
Przyborski (Marburg, Germany). Plasmid extractions were carried out using an alkaline 
extraction method, as described by Birnboim et al. (1979). Sterile Luria Broth (LB) 
(20ml), containing 100µg/ml ampicillin (20µl of 100mg/ml ampicillin stock), was 
inoculated with E. coli plasmid glycerol stock (10-200µl), in an aseptic environment. The 
culture was incubated at 37˚C in a shaking incubator (225-250 rpm) for 16-18 hours. A 
Thermo Biomate 5 Spectrophotometer (Merk, Germany), was used to measure the optical 
density (OD) of the culture, at 600nm, to check for bacterial growth. When OD600 readings 
were found to be higher than 2.0, cells were harvested. If readings were lower than 2.0, 
cultures were returned for further incubation. Bacterial cells were harvested in 15ml 
centrifuge tubes (Greiner bio-one, Germany) by centrifugation at 3000 x g for 10 minutes 
at 4˚C (Eppendorf Centrifuge 5702R, Germany). The pellets were then re-suspended in 
0.05 volumes of ice cold re-suspension solution (1ml). After 5 minutes incubation at room 
temperature, 0.1 volumes of lysis solution (2ml) was added to the suspension, and mixed 
by gentle inversion. The solution was then neutralized by the addition of 0.075 volumes of 
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ice cold neutralizing solution (1.5ml), followed by 5 minutes incubation on ice. The 
released plasmid DNA was then separated from the lysed cells and denatured material by a 
further 20 minute centrifugation. The supernatant, containing the plasmid DNA, was 
transferred to sterile 2ml microcentrifuge tubes (Eppendorf, Germany) and 0.2 volumes of 
1:1 phenol:chloroform (1ml for every tube containing 1ml supernatant) was added, to aid 
in plasmid purification. The solution was separated by 5 minutes centrifugation, 3000 x g 
at 4˚C (Eppendorf Centrifuge 5415 R, Germany). The supernatant, containing the plasmid 
DNA, was transferred to fresh 1.5ml microcentrifuge tubes (Eppendorf, Germany), before 
adding 3 volumes of ice cold 100% ethanol (1.2ml for every tube containing 400µl 
supernatant). The solution was incubated at room temperature for 5 minutes, followed by 
10 minutes centrifugation. The supernatant was then decanted, and the plasmid-containing 
pellet was air dried. The pellet was re-suspended in 800µl TE buffer, containing 100µg/ml 
RNase A (8µl of 10mg/ml stock), and incubated at 37˚C for 30 minutes, allowing 
contaminating RNA to be removed. The solution was neutralized by the addition of 80µl 
cold neutralizing solution. One millilitre of 1:1 phenol:chloroform was added and the 
phases were separated by 5 minutes centrifugation at 3000 x g at 4˚C. The aqueous phase, 
devoid of RNase A and degraded RNA, was transferred to sterile 2ml microcentrifuge 
tubes. To precipitate the plasmid DNA, 0.1 volumes of 3M sodium acetate and 2.5 
volumes of ice cold 100% ethanol were added and the solution was incubated at -70˚C for 
a minimum of 15 minutes. Upon removal from the freezer, DNA was pelleted at 3000 x g 
at 4˚C for 30 minutes. The supernatant was decanted and the pellet was washed with 1ml 
70% ethanol (5 minutes centrifugation at max speed) before being air dried. Final re-
suspension was in ~100µl of nuclease free water, followed by 15 minutes incubation at 
room temperature to aid in re-suspension of the DNA. The resulting products were 
analysed by electrophoresis as per 2.3 and stored at -20˚C. 
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2.4.2. Plasmid preparation for transfections 
Large amounts of purified plasmid (>100µg) are required to transfect P. falciparum 
parasites. To achieve this, the NucleoBond® Xtra Maxi kit for Plasmid DNA Purification 
(MN, Germany) was used. This preparation relies on the principle of anion-exchange. The 
NucleoBond® Xtra anion-exchange columns and column filters are designed to allow 
solutions to be passed through by gravity flow. Starter cultures of 5ml sterile LB, 
containing 100µg/ml ampicillin (5µl of 100mg/ml ampicillin stock), were inoculated with a 
scraping of plasmid glycerol stocks. The culture was allowed to grow for 8 hours at 37˚C, 
shaking at 225- 250 rpm. Bacterial growth was then measured as in 2.4.1. OD600 readings 
of 0.3 or more indicated that bacteria were in exponential growth phase and therefore ready 
for re-inoculation. Larger LB (containing100µg/ml ampicillin) volumes of 250ml were 
then inoculated with 1ml of starter culture. The larger cultures were allowed to grow for no 
longer than 17 hours under the same conditions as the starter cultures. The ODs of the 
cultures were again measured as in 2.4.1, to ensure sufficient bacterial growth (OD600 
higher than 2). Cultures were transferred to 250ml centrifuge tubes (Beckman, USA) and 
bacterial cells were harvested by centrifugation at 6000 x g at 4˚C for 15 minutes, using an 
Avanti® J-E Centrifuge (Beckman Coulter, USA). The kit’s protocol for low-copy plasmid 
purification was followed, as pARL plasmids are low-copy number plasmids. Volumes of 
the Resuspension, Lysis, Neutralization and Elution buffers used in this procedure, were 
determined by the formula:  =   X !"## / 50. To desalinate and 
concentrate the eluted DNA, NucleoBond® Finalizers were used. This system allows the 
solution to be filtered by means of a silica membrane. The final product was eluted from 
the Finalizer membrane with 1ml of TE Buffer, and passed through the filter for a second 
time to increase purity. The plasmid DNA was stored at -20˚C. 
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2.5. Primer design 
2.5.1. Primer specifications and parameters 
Sequences of the relevant P. falciparum genes, jesebl (PF3D7_0102500), maebl 
(PF3D7_1147800.1) and apical membrane antigen-1 (ama-1) (PF3D7_1133400) were 
obtained from the Plasmodium genome database, PlasmoDB version 8.2 
(http://plasmodb.org/plasmo/). Primers were designed using Integrated DNA Technologies 
SciTools OligoAnalyzer (www.idtdna.com). A list of all primer sequences may be found in 
appendix C. Recognition sites for the restriction enzymes (REs) XhoI, AvrII and NotI were 
included in the design of the primers, to allow ligation of the amplified products into the 
pARL2-GFP and pARL-mCherry vectors. For overlap-extension PCR, overlapping 
sequences were added to the ends of primers, thereby allowing the resulting products to be 
connected to one another. This principal is represented in figure 7. The criteria used to 
design the primers included minimal hair-pin and primer-dimer formation, and melting 
temperatures of no less than 45˚C for the P. falciparum-specific template. Primer 
sequences were also checked against the Plasmodium genome database by means of a 
BLAST search, to ensure minimal non-specific binding. Primer synthesis was out-sourced 
to Inqaba Biotech (South Africa). Primers were received in lyophilised form and dissolved 
in the recommended amounts of nuclease-free water, to make a final concentration of 
100µM. Primer dilutions of 10µM and 2µM were made from the 100µM stocks and all 
were stored at -20˚C.  
  
 
 
 
2.5.2. Regions chosen for amplification
2.5.2.1. maebl 
The maebl SP (1-174) and 
(figure 8). The CT starts directly after the TM and its sequence ends at the end of the 
maebl coding sequence (6031
span the last 104 residues of the second exon and immediately precede the 
sequence information and comparison of the 
coding sequence (Treeck 
Importantly, the chosen CCys region contained all eight
  
Figure 7. Schematic diagram representing 
Overlapping ends are shown by solid black rectangles. PCR products are repr
letters. The open rectangular box shows the PCR reaction whereby the two regions are joined 
together. 
 
 
TM (5959-6030) sequences are available on the 
-6168). Adams et al. (1992) described the 
maebl coding sequence to the 
et al., 2006) were used to define this region
 conserved cysteine ami
overlap extension PCR using primers 
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PlasmoDB 
CCys region to 
TM. This 
eba-175 CCys 
 as 5619-5958. 
no acids. 
a,b,c & d. 
esented by capital 
  
 
2.5.2.2. jesebl 
The jesebl SP sequence (1
sequence (4179-4461) was designed by comparison with the 
sequence, so as to contain the eight
 
 
 
 
2.5.2.3. The ama-1 promoter region
Primers used to amplify the 
genomic sequence directly upstream of the start of the 
al., 2000). The ama-1 genomic and coding sequences are available on 
     
2.6. cDNA synthesis 
First-strand cDNA was synthesized from 5
PCR reaction using SuperScript
recommended protocol. The 5
Figure 8. Schematic representation of the 
base pair positions are shown.
Figure 9. Schematic representation of the 
base pair positions are shown.
-108) is available on PlasmoDB. The jesebl
eba-
 conserved cysteine amino acids (figure 9
 
ama-1 promoter region were designed to amplify 1455bp of 
ama-1 coding sequence (Triglia
PlasmoDB
µg total parasite RNA in a reverse
TM
 III Reverse Transcriptase (Invitrogen), following the 
µg of total RNA was transferred to a sterile, nuclease
maebl coding sequence. Domains and their relevant 
 
jesebl coding sequence. Domains and their relevant 
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 CCys coding 
175 CCys coding 
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-transcription 
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0.6ml microcentrifuge tube (QSP, USA). To the tube the following was added: 2 pmol of 
gene-specific antisense primer (1µl of 2µM stock), 1µl of 10mM dNTP Mix and nuclease-
free water up to 13µl. The reaction was then heated to 65˚C for 5 minutes, using a 
Mastercycler Gradient thermocycler (Eppendorf, Germany), and then incubated on ice for 
1 minute. This incubation allows the primer to bind to the RNA. To complete the reverse 
transcription reaction, 4µl of 5X First-Strand Buffer (1X final concentration), 1µl of 0.1M 
DTT (5mM final concentration), 40 units of the RNase inhibitor, RiboLock (1µl of 40U/µl 
stock), and 200-400 units of SuperScriptTM III RT enzyme (1-2µl of 200U/µl stock) were 
added to the reaction, to a final volume of 20µl. The tube was incubated at 55˚C for 1 hour, 
followed by an inactivation step of 15 minutes at 70˚C. One microlitre of the cDNA was 
used per subsequent PCR and the remainder was stored at -20˚C.    
 
2.7. PCR 
All PCR reactions were carried out using a Mastercycler Gradient Thermocycler 
(Eppendorf, Germany). Reactions were always started at a temperature of 94˚C. Resulting 
PCR products were analysed spectrophotometrically using a Nanodrop 1000 
(Thermospecific, USA), and visualised as per 2.3.  
 
Reactions were performed using High Fidelity PCR Enzyme Mix (Fermentas, Europe) or 
Go Taq® Green Master Mix (Promega, USA). The High Fidelity enzyme mix was used 
because it contains a blend of DNA polymerases with high proofreading activity, and it is 
able to amplify products up to 10kb in length. These products may then be used in further 
reactions. To the template DNA, in a 0.6ml nuclease-free microcentrifuge tube (QSP, 
USA), the following was added: 5µl of 10X High Fidelity PCR Buffer (containing 15mM 
MgCl2), 5µl of 10mM dNTP mix, 0.5 or 1µM of gene-specific antisense primer (2.5µl or 
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5µl of 10µM stock), 0.5 or 1µM of gene-specific sense primer (2.5µl or 5µl of 10µM 
stock), 1.25 or 2.5 units of High Fidelity PCR Enzyme Mix (0.25µl or 0.5µl of 5U/µl stock, 
depending on the length of the desired product) and nuclease-free water up to 50µl. 
 
Go Taq® Green Master Mix was used in PCRs when it was only required to visualize the 
resulting products. The Go Taq® enzyme allows erroneous bases to be incorporated into 
amplicons rendering the product inappropriate for use in further experiments. Reactions 
were carried out in 0.6ml nuclease-free microcentrifuge tubes as follows: 12.5µl Go Taq® 
Green Master Mix, 0.8 or 1µM of gene-specific primers (2µl or 2.5µl of 10µM stocks), 
200-300ng template DNA and nuclease-free water up to a final reaction volume of 25µl.  
 
The PCR thermal cycling conditions varied according to the template DNA and primers 
used. As per the High Fidelity PCR Enzyme Mix recommendations, all protocols included 
an initial denaturation at 94˚C for 2 minutes and 25-35 cycles. Thermal cycles included 
three temperature changes for denaturation, annealing and extension. Denaturation 
temperature and time were based on manufacturer recommendations and annealing 
temperatures were based on primer melting temperatures, calculated using Integrated DNA 
Technologies SciTools OligoAnalyzer (www.idtdna.com). It is recommended to use an 
extension temperature of 72˚C however, the P. falciparum genome is very AT-rich, 
making the lower extension temperature of 68˚C more suitable. Extension times were 
based on length of the product, 1 minute per kilobase. 
 
2.7.1. PCR to amplify maebl and jesebl gene domains 
For primers containing DNA sequence overhangs, two annealing temperatures were used. 
These temperatures were based on the melting temperature of the whole primer and that of 
 the template-specific portion 
template-specific portion of the primer to bind to the template. Once the added bases have 
been incorporated into the PCR product, the second annealing temperature allows the 
whole primer to bind to the desired product. Pri
only one annealing temperature. Optimal PCR thermal cycling conditions were set as 
follows: 
 
Amplification of the maebl
M-AS3 (figure 10): 
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 30 seconds
Primer annealing: 52˚C for 1 minute, 5 cycles and then 58˚C for 1 minute, 27 cycles
Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
 
 
 
 
Amplification of the maebl 
AS1 and maebl TM-CT only from
12): 
Initial denaturation: 94˚C for 2 minutes
Figure 10. The maebl coding sequence showing SP specific primers. Forward primer: M
XhoI restriction site (black circle). Reverse primers: M
green lines). 
of the primer only. The first annealing temperature allows the
mers without added overhangs
 SP from cDNA, using primers M-S1 and M
 
 
 
 
CCys, TM and CT from cDNA, using primers M
 cDNA, using primers M-S3 and M-AS1
 
-AS2 & M-AS3 with overhangs (red and 
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 required 
-AS2 or M-S1 and 
 
 
-S2 and M-
 (figures 11 and 
-S1 with 
 Denaturation: 94˚C for 30 seconds
Primer annealing: 45˚C for 1 minute, 30 cycles 
Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
 
 
 
 
 
Amplification of the jesebl 
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 30 seconds
Primer annealing: 49˚C for 1 minute, 5 cycles and then 58˚C for 1 minute, 27 cycles
Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
 
 
Figure 11. The maebl coding sequence showing CCys
M-S2 (complementary to M
(black circle). 
Figure 12. The maebl coding sequence showing TM
(complementary to M-AS3 overhang). Reverse primer: M
circle). 
Figure 13. The jesebl coding sequence showing SP specific primers. Forward primer: J
XhoI restriction site (black circle). Reverse primer: J
 
 
 
 
SP from cDNA, using primers J-S1 and J-AS3
 
 
 
 
-TM-CT specific primers. Forward primer: 
-AS2 overhang). Reverse primer: M-AS1 with 
-CT specific primers. Forward primer: M
-AS1 with AvrII restriction site (black 
-AS3 with overhang (red line).
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 (figure 13): 
 
 
AvrII restriction site 
-S3 
-S1 with 
 
 Amplification of the jesebl 
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 30 seconds
Primer annealing: 45˚C for 1 minute, 30 cycles 
Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
 
 
 
2.7.2. Overlap extension PCR
Overlap extension PCR is used to join to PCR fragments together and re
resulting product (Ho et al.
of the PCR products to be joined together. Two different annealing temperatures w
incorporated into the PCR conditions. The first annealing temperature allows the two over
lapping ends to anneal to each other while the second annealing temperature is optimal for 
primer annealing and, therefore, amplification of the product. The PCR 
as follows: 
 
To join the maebl SP to the 
join maebl SP to the maebl 
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 30 seconds
Primer annealing: 45˚C for 1 minute, 5 cycles and then 58˚C for 1 minute, 25 cycles
Figure 14. The jesebl coding sequence showing CCys specific primers. Forward primer: J
(complementary to J-AS3 overhang). Reverse primer: J
circle). 
CCys from cDNA, using primers J-S2 and J-
 
 
 
 
 
 
, 1989). The template for the reaction consisted of 2
maebl CCys-TM-CT using primers M-S1 and M
TM-CT using primers M-S1 and M-AS1 (figures 15 and 1
 
 
-AS4 with AvrII restriction site (black 
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AS4 (figure 14): 
 
-amplify the 
µl of each 
ere 
-
conditions were set 
-AS1; and to 
6): 
 
-S2 
 Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
 
 
 
 
 
 
To join the jesebl SP to the 
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 30 seconds
Primer annealing: 45˚C for 1 minute, 5 cycles and then 60˚C for 1 minute, 25 cycles
Extension: 68˚C for 1 minute
Final extension: 68˚C for 10 minutes
Figure 15. Overlap extension PCR to join 
S1 with XhoI restriction site (black circle). Reverse primer: M
(black circle). Restriction sites are incorporated into the resulting product (black rectangles).
Figure 16. Overlap extension PCR to join 
with XhoI restriction site (black circle). Reverse primer: M
circle). Restriction sites are incorporated into the resulting product (black rectangles).
 
 
 
jesebl CCys using primers J-S1 and J-AS4 (figure 1
 
 
 
 
maebl SP to maebl CCys-TM-CT. Forward primer:
-AS1 with Avr
maebl SP to maebl TM-CT. Forward primer: M
-AS1 with AvrII restriction site (black 
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7): 
 
 M-
II restriction site 
 
-S1 
 
  
 
 
2.7.3. PCR to amplify the ama
The endogenous crt promoter was exchanged with the 
and pARL-mCherry vectors, to ensure stage
ama-1 promoter region is exceptionally AT
problematic. The amplification reaction was optimised using Go
(Promega, USA) and varying conditions. The final product was amplified with High 
Fidelity PCR Enzyme Mix (Fermentas, Europe) using the optimised conditions. 
 
2.7.3.1. Reactions employing Go Taq® Green Master Mix (Promega, USA)
The ama-1 promoter region was amplified from 200
DNA (provided by Warren A. Vieira
Haematology, the University of the Witwatersrand
The PCR conditions were as
Initial denaturation: 94˚C for 2 minutes
Denaturation: 94˚C for 1 minute
Primer annealing: 39.3˚C-43.0
24-30 cycles  
Extension: 62˚C, 63˚C, 64˚C or 68˚C for 2 minute
Figure 17. Overlap extension PCR to join 
XhoI restriction site (black circle). Reverse primer: J
circle). Restriction sites are 
 
-1 promoter region 
ama-1 promoter in the pARL2
-specific expression of chimaeric proteins. The 
-rich (86%) which made amplification 
 Taq® Green Master Mix 
-500ng of P. falciparum
, department of Molecular Medicine and 
), using primers AMA
 follows: 
 
 
˚C for 1 minute, 5 cycles and then 56˚C-
s 
jesebl SP to jesebl CCys. Forward primer: J
-AS4 with AvrII restriction site (black 
incorporated into the resulting product (black rectangles).
50 
-GFP 
 
 
 genomic 
-S and AMA-AS. 
58˚C for 1 minute, 
-S1 with 
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Final extension: 62˚C, 63˚C, 64˚C or 68˚C for 10 minutes 
 
2.7.3.2. Reactions employing High Fidelity PCR Enzyme Mix (Fermentas, Europe) 
The ama-1 promoter region was amplified from 200ng of P. falciparum genomic DNA 
(provided by Warren A. Vieira), using primers AMA-S and AMA-AS. Reactions using an 
extension temperature of 68˚C were unsuccessful due to the extremely AT-rich nature of 
this region, therefore, 64˚C was used. The PCR conditions were as follows: 
Initial denaturation: 94˚C for 2 minutes 
Denaturation: 94˚C for 1 minute 
Primer annealing: 42.6˚C for 1 minute, 5 cycles and then 58˚C for 1 minute, 24 cycles  
Extension: 64˚C for 2 minutes 
Final extension: 64˚C for 10 minutes 
 
2.8. PCR product and plasmid purification 
All PCR products containing only the desired amplicon were purified using a QIAquick® 
PCR Purification Kit (Qiagen, UK). This process was necessary as High Fidelity 
components interfere with the action of REs, in subsequent reactions. Products were also 
purified post RE and plasmid dephosphorylation reactions, so as to remove the enzymes 
and other reagents before ligation. The protocol was followed as per the manufacturer’s 
instructions. The QIAquick columns contain an anion-exchange resin which allows DNA 
to bind at high salt concentrations and low pH conditions. A pH-indicator showed the 
alkalinity of the sample to be purified. A sample with a pH greater than 7.5 turned violet in 
the presence of the indicator. In this case, 10µl of 3M Sodium acetate (pH 5) was added to 
reactions to decrease the pH to 7.5 or less, changing the indicator yellow and, therefore, 
allowing the DNA to bind to the resin. After impurities were washed away, the DNA was 
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eluted in a more alkaline medium. For this purpose, 20-60µl of Buffer EB (Tris Buffer, pH 
8.5) or nuclease free water was used. Eluted DNA was stored at -20˚C. 
 
2.9. Gel Extraction 
When PCR reactions resulted in non-specific amplicons, the product of interest was 
extracted from a standard 1% or 0.8% agarose gel using the QIAquick® Gel Extraction Kit 
(Qiagen, UK). The kit makes use of the same principal as the QIAquick® PCR Purification 
Kit (Qiagen, UK) mentioned in section 2.8. This kit was used as it allows a high recovery 
of purified DNA. The fragment of interest was visualized using a UV Transilluminator 
(UVP LLC, UK). It was then excised from the gel under UV light, using a clean, sharp 
scalpel and weighed in a colourless microcentrifuge tube (Eppendorf, Germany). Excision 
was carried out in the shortest possible time, as the UV light damages nucleic acids. DNA 
was purified from the gel slice according to the manufacturer’s recommendations. For the 
elution, 30µl of nuclease-free water was used. Samples were visualised by gel 
electrophoresis (refer to 2.3) before storage at -20˚C.  
 
2.10. Cloning 
2.10.1. Enzyme Digestion 
Gene Tools imaging software (SynGene, UK) was used to quantify PCR products 
separated by agarose gel electrophoresis. The products, to be inserted into the pARL2-GFP 
and pARL-mCherry vectors, were digested with the FastDigest® REs (Fermentas, Europe) 
in 30µl reaction volumes (table 100). One microlitre of each of these REs is able to digest 
up to 1µg of DNA in minimal time, with no star activity, using a universal buffer. 
Reactions were set up in 0.6ml microcentrifuge tubes (QSP, USA) as follows: 500-1900ng 
PCR product DNA, 2µl 10X FastDigest® Buffer, 1µl F FastDigest® RE #1, 1µl FastDigest® 
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RE #2 and nuclease-free water up to 30µl. The reactions were incubated at 37˚C for 15- 20 
minutes, to allow the enzymes to digest the PCR products at their terminal restriction sites. 
Plasmid DNA was digested in a 20µl reaction as follows: ±1µg Plasmid DNA, 2µl 10X 
FastDigest® Buffer, 1µl FastDigest® RE #1, 1µl FastDigest® RE #2, 1µl FastAPTM 
Thermosensitive Alkaline Phosphatase (Fermentas, Europe) and nuclease-free water up to 
20µl (table 1). These reactions were incubated at 37˚C for 3.5-4 hours. Even though 
incubation time is recommended to be 5 minutes, longer times were used to ensure optimal 
digestion and dephosphorylation. All digestion products were then purified as per 2.8 and 
eluted in 20- 30µl nuclease-free water before storage at -20˚C.   
 
Table 1. Templates and enzymes employed in enzyme digestions. 
Template RE #1 RE #2 FastAP 
PCR product 
ama-1 promoter XhoI NotI No 
M1 XhoI AvrII No 
M2 XhoI AvrII No 
J XhoI AvrII No 
Plasmid 
pARL-mCherry XhoI NotI Yes 
pARL2-GFP XhoI NotI Yes 
pARL-mCherry/ama-1 promoter XhoI AvrII Yes 
pARL2-GFP/ama-1 promoter XhoI AvrII Yes 
RE- Restriction enzyme 
FastAP- Thermosensitive Alkaline Phosphatase (Fermentas, Europe) 
 
2.10.2. Ligation 
Purified RE-digested PCR products and plasmid DNA were separated on the same agarose 
gel, to be quantified with Gene Tools imaging software (SynGene, UK). The ligation molar 
ratio of insert DNA to vector DNA was calculated at 3:1, with approximately 200ng total 
DNA. To perform these calculations, the In-Fusion® Molar Ratio Calculator 
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(http://bioinfo.clontech.com/infusion/molarRatio.do) was used. The Rapid DNA Ligation 
Kit (Roche Applied Science, Germany) was used to perform ligations. The vector and 
insert DNA were added to 2µl 5x DNA Dilution Buffer and nuclease-free water up to a 
volume of 10µl. T4 DNA Ligation Buffer (10µl) and 1µl T4 DNA Ligase were then added 
to the reaction and mixed. To allow ligation, the reaction was incubated at 16˚C for 0.5-3 
hours. Controls were included for each ligation reaction, whereby the insert DNA was 
replaced by nuclease-free water. Colonies present on control plates indicated that plasmid 
DNA was either incompletely digested by REs, leaving plasmid in circular form, or 
dephosphorylation by alkaline phosphatase was incomplete, allowing linear plasmid to re-
ligate into circular form.  
 
2.10.3. Transformation 
The ligation products were used to transform E. coli XL10-Gold Competent Cells (Agilent 
Technologies, South Africa). Growth tubes (14ml, BD Falcon, USA) were chilled on ice 
before adding 50-100µl competent cells and 2-4µl β-Mercaptoethanol. The manufacturer’s 
protocol recommends 100µl, however, it was found that transformations were adequate 
using half the reaction volume. The tubes were incubated on ice for 10 minutes with gentle 
swirling every 2 minutes before adding 6µl ligation mix. Tubes were incubated on ice for a 
further 30 minutes before heat-pulsing for 30 seconds at 42˚C, followed by incubating on 
ice for 2 minutes. LB was pre-heated to 42˚C and 400µl of this was added to each growth 
tube to make a final volume of ~500µl. One hour incubation at 37˚C, shaking at 225-250 
rpm, allowed transformed cells to propagate before they were plated (in a sterile 
environment) on agar plates containing 100µg/ml ampicillin. For each transformation, 50µl 
of cells were spread on one plate and the remaining 450µl on a second plate, and both were 
incubated at 37˚C, upside-down for 18- 24 hours. It was expected that the plate containing 
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50µl of transformed cells would show a moderate amount of bacterial colonies, and the 
other plate would show bacterial growth of approximately nine times that of the 50µl plate. 
If this was not the case, it showed a low level of transformation efficiency. Furthermore, it 
was expected to observe no or very little growth on control plates.  
 
2.11. Verification of transformation results 
2.11.1. Colony PCR 
Sterile 10µl plastic pipette tips were used to pick 5-10 single colonies from each of the 
plates containing transformed colonies. For each control plate, 2 colonies were picked. The 
colonies were each resuspended in 10µl of nuclease-free water. Half of each resuspension 
(5µl) was added to a PCR reaction and the other half was used for plasmid preparation (see 
2.11.2). In a 0.6ml microcentrifuge tube (QSP, USA), the following reagents were added to 
the 5µl suspension: 12.5µl Go Taq® Green Master Mix (Promega, USA), 0.8µM of each of 
the appropriate forward and reverse primers (2µl of 10µM stocks, table 2), and nuclease-
free water to make up 25µl. The PCR reactions were performed using a Mastercycler 
Gradient Thermocycler (Eppendorf, Germany), and the appropriate protocol. The resulting 
PCR products were analysed by gel electrophoresis, as per 2.3, to inspect the presence or 
absence of the desired products.  
 
Table 2. Primers used in Colony PCR reactions. 
Plasmid used in transformation Forward primer Reverse primer 
pARL-mCherry/ama-1 promoter AMA-S AMA-AS 
pARL-mCherry/J J-S1 J-AS4 
pARL2-GFP/M1 M-S1 M-AS1 
pARL2-GFP/M2 M-S1 M-AS1 
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2.11.2. Plasmid preparation and enzyme digestion 
Plasmid DNA was extracted from transformed colonies that were found to be positive by 
the PCR screen (2.11.1). Single colony resuspensions (5µl) were added to 3ml sterile LB 
containing 100µg/ml ampicillin (3µl of 100mg/µl stock) in 25ml glass flasks, and 
incubated at 37˚C for 18-24 hours, shaking at 225-250 rpm. Of the 3ml colony culture, 
1.5ml was made into stocks and DNA was extracted from the other 1.5ml. To create 
stocks, 500µl of the culture was added to 500µl 60% glycerol and frozen at -70˚C. Plasmid 
preparations were carried out using the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich, 
USA), following the manufacturer’s instructions. The kit makes use of an alkaline-SDS 
lysis procedure followed by silica-binding technology to produce pure plasmid 
preparations. The plasmid DNA was eluted in 50µl of nuclease-free water and used 
directly for RE digestions, to determine if the desired insert was present. The enzyme 
reactions were set up in 0.6ml microcentrifuge tubes (QSP, USA) containing 5µl purified 
plasmid, 2µl of FastDigest® Buffer, 1µl of each of the FastDigest® REs (Fermentas, 
Europe) and 11µl nuclease-free water. Reactions were incubated at 37˚C for 15 minutes to 
1 hour, to ensure sufficient digestion. The resulting DNA fragments were visualized by 
electrophoresis (refer to 2.3). 
    
2.11.3. Sequencing  
Plasmid preparations found to contain ligated inserts (as determined by 2.11.1 and 2.11.2) 
were chosen for sequencing. Agar plates (containing 100µg/ml ampicillin) were streaked 
with the corresponding glycerol stock, and incubated at 37˚C for 18-24 hours. The plates 
were then sent to Inqaba Biotech for sequencing. Sequencing primers were designed and 
produced by Inqaba Biotech to recognise sequence segments within plasmid backbones 
and within the inserts, as required. The sequences of these primers remain the intellectual 
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property of Inqaba Biotech. Results were provided in Finch TV format and sequences were 
manually compared to the desired sequence to screen for nucleotide changes, insertions or 
deletions. 
   
2.12. Transfections of P. falciparum erythrocyte-stage parasites 
2.12.1. Preparation of parasites for transfection  
Cultures consisting of 5% ring-stage parasites were used for transfections. To achieve this, 
two rounds of D-Sorbitol synchronization were carried out 48 hours apart, as per 2.1.8. The 
5ml culture was transferred to a 15ml centrifuge tube (Greiner bio-one, Germany) and 
centrifuged at 1400 x g for 5 minutes at 4˚C (Eppendorf Centrifuge 5702 R, Germany). 
The pellet, containing the parasitized erythrocytes, was then used immediately for the 
transfection. 
 
2.12.2. Preparation of plasmid for transfection 
Plasmids were extracted using the NucleoBond® Xtra Maxi kit for Plasmid DNA 
Purification (MN, Germany) and eluted in 1ml TE buffer as per 2.4.2. A 1:10 dilution of 
the preparation was made in nuclease free water, and 2µl of the dilution was linearized 
with a RE. In a microcentrifuge tube (Eppendorf, Germany), the following were added to 
the plasmid DNA: 2µl 10X FD Green Buffer, 1µl FD RE, and nuclease-free water up to 
20µl. Digestion was carried out at 37˚C for 10-15 minutes. The whole 20µl reaction was 
loaded into a 1% agarose gel and electrophoresed (refer to 2.3) for the resulting product to 
be quantified by Gene Tools imaging software (SynGene, UK). Quantification indicated 
total yields ranging from 100µg to 500µg of purified plasmid per 1ml concentrated eluate.  
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Plasmid preparations of 100µg to 300µg were concentrated, to be used for transfections. To 
achieve this, 1 volume of 1:1 phenol:chloroform was added to and mixed with the plasmid 
eluate. The mixture was centrifuged at 3000 x g for 5 minutes at 4˚C (Eppendorf 
Centrifuge 5415 R, Germany) and the upper aqueous phase, containing the plasmid DNA, 
was transferred to a fresh 1.5ml microcentrifuge tube. An equal volume of chloroform was 
then added to and mixed with the solution and centrifugation was repeated. The upper 
aqueous phase was again transferred to a fresh tube and to it 1/10 volume 3M sodium 
acetate and 2.5 volumes 100% ethanol were added to precipitate the DNA. The tube was 
then stored at -70˚C for a minimum of 15 minutes, to aid in the precipitation. 
Centrifugation was carried out at maximum speed (16100 x g) for 30 minutes at 4˚C to 
ensure all DNA was pelleted in the tube. The supernatant was removed and the pellet was 
washed with 70% ethanol, air-dried, resuspended in 30µl TE buffer and used immediately 
for the transfection. 
 
2.12.3. Preparation of erythrocytes for transfection 
Fresh whole blood collected from a volunteer in a 6ml acid citrate dextrose tube (Becton 
Dickinson Biosciences, USA), was centrifuged at 1000 x g for 10 minutes at 4˚C. The top 
buffy and plasma layers were aspirated and the packed erythrocytes were used immediately 
for transfections. 
 
2.12.4. Transfection procedure 
Transfections were carried out in a sterile hood. The 30µl of concentrated plasmid, 200µl 
of packed erythrocytes and 370µl of pre-warmed (at 37˚C) cytomix were mixed and added 
to a 2mm sterile cuvette (BioRad, USA). The cuvette content was electroporated using a 
Gene Pulser XcellTM (BioRad, USA) electroporator set to 310V and 950µF. Time and 
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actual voltage were recorded. Electroporation time should range between 12 and 15 
milliseconds (ms). The content of the cuvette was then transferred to a small (25cm3) 
culture flask (Nunc, Denmark), using complete medium to wash out the cuvette and aid 
transfer. To the flask, parasites were added to make a final concentration of ~1% 
parasitaemia and complete medium to make a final volume of 5ml before gassing as per 
2.1.1. A smear was prepared and the medium was changed the day following the 
transfection. On the second day post-transfection, medium was changed, slides were 
prepared and the selective drug WR99210 (kindly provided by Dr Jude M. Przyborski, 
Marburg, Germany) was added to a final concentration of 2nM (1µl of 10µM stock). 
Parasites that had taken up the episomal plasmid gained resistance to the WR99210 drug as 
the plasmid contains the dihydrofolate reductase (dhfr) gene. Transfected cultures were 
kept under continual drug pressure with tri-weekly medium changes and smear 
preparations. In addition, fresh packed erythrocytes were added to the culture weekly 
(100µl), to replenish haematocrit to 5% while parasitaemia was too low to be visualized. It 
took 25-30 days for parasitaemia to be high enough for parasites to be visualized on 
smears. 
 
2.13. Verification of transfection by DNA extraction and PCR analysis 
DNA was extracted from a 5ml culture of transfected parasites, using the hypotonic lysis 
protocol (Cowman et al., 2008). The culture was transferred to a 15ml centrifuge tube 
(Greiner bio-one, Germany) and centrifuged at 1000 x g for 5 minutes at 4˚C. After 
removal of the supernatant, the pellet was resuspended in 14ml PBS. The centrifugation 
was repeated and the pellet was then resuspended in 4 volumes (approximately 1ml) of 
hypotonic solution, allowing the erythrocytes to be lysed. To remove proteins, 1 volume 
(approximately 250µl) of 18% SDS was added to the suspension and vortexed before 
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incubation at room temperature for 2-3 minutes. A phenol:chloroform purification was 
performed to remove salts and contaminants, whereby 8 volumes  (approximately 2ml) of 
1:1 phenol:chloroform was added and the suspension was centrifuged at 3000 x g for 10 
minutes at 4˚C. The upper aqueous phase, containing the parasite DNA (including 
episomal plasmids), was transferred to a 1.5ml microcentrifuge tube (Eppendorf, 
Germany) and DNA was precipitated as per 2.12.2. The resulting pellet was dissolved in 
600µl TE buffer, with the addition of 10µg RNase A (1µl of 10mg/ml stock) and incubated 
at 37˚C for 30 minutes, to remove contaminating RNA from the sample. DNA was again 
extracted by a phenol:chloroform purification, using 1 volume (600µl) of 1:1 
phenol:chloroform. One volume (600µl) of chloroform was added to the aqueous phase 
and the sample was centrifuged at maximum speed (16100 x g) for 5 minutes at 4˚C 
(Eppendorf Centrifuge 5415 R, Germany). As before, the upper DNA-containing aqueous 
phase was transferred to a fresh microcentrifuge tube and DNA was again precipitated as 
per 2.12.2. The final pellet, consisting of pure parasite genomic and episomal DNA, was 
dissolved in 50µl TE buffer, incubated at room temperature for 15 minutes and then used 
for PCR or stored at 4˚C.  
 
To test for the presence of the appropriate plasmid within the transfected parasites, a PCR 
was performed. Approximately 300ng DNA was amplified in a 25µl reaction volume with 
Go Taq® Green Master Mix (Promega). A forward vector-specific primer and a reverse 
insert-specific primer were used at a final concentration of 1µM (2.5µl of 10µM stocks), 
and nuclease-free water was used to make up the reaction volume. Appropriate positive 
(plasmid purified from bacterial stocks) and negative (3D7 parasite DNA obtained from 
Warren A. Vieira) controls were included to verify PCR results (table 3). The reaction was 
carried out using a Mastercycler Gradient thermocycler (Eppendorf, Germany), set at 94˚C 
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for 2 minutes, followed by 35 cycles of 94˚C, 55˚C and 68˚C for 1minute each, and a final 
extension period of 10 minutes at 68˚C. Gel electrophoresis was used to visualize PCR 
products as per 2.3. 
 
Table 3. Templates and primers used for PCR verification of transfectants. 
Transfectants Templates Primers 
pARL-mCherry control DNA extracted from parasites pARL-S/ mC-AS 
Purified plasmid (positive control) 
3D7 DNA (negative control) 
pARL2-GFP control DNA extracted from parasites pARL-S/ GFP-AS 
Purified plasmid (positive control) 
3D7 DNA (negative control) 
pARL-mCherry/J DNA extracted from parasites pARL-S/ J-AS4 
Purified plasmid (positive control) 
3D7 DNA (negative control) 
pARL2-GFP/M1 DNA extracted from parasites pARL-S/ M-AS1 
Purified plasmid (positive control) 
3D7 DNA (negative control) 
pARL2-GFP/M2 DNA extracted from parasites pARL-S/ M-AS1 
Purified plasmid (positive control) 
3D7 DNA (negative control) 
 
2.14. Microscopy studies 
2.14.1. Live imaging 
To view the fluorescently labelled live parasites, 70µl of incomplete medium was added to 
30µl of whole culture. To this mixture, 4µl of 1:100 diluted DAPI (blue nuclear stain) was 
added and incubated in the dark for 5 minutes due to the light sensitivity of the stain. The 
erythrocytes were pelleted by centrifugation at 1000 x g for 3 minutes at room temperature 
(Eppendorf Centrifuge 5415 R, Germany), and washed with 1ml incomplete medium. The 
final pellet was diluted with 200µl incomplete medium and used directly for viewing.  
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A 5µl aliquot of the stained suspension was used to spot a glass microscope slide (Lasec, 
South Africa), which was then covered by a glass cover slip. The cells were viewed under 
63x magnification on an Olympus BX63 fluorescence microscope with a UPLSAPO 100x/ 
1.4 objective lens. Multi-channel mirror cubes U-FDICT, U-FBNA, U-FYW and U-FUNA 
were used to view DIC Grey (550nm) and GFP (510nm), mCherry (610) and DAPI 
(455nm) fluorescence respectively (table 4). A DP80 (1x1 Binning) camera (Olympus, 
Japan) with 0.63 adapter magnification was used in conjunction with CellSense Dimension 
software for photographing and editing the fluorescent images. 
 
Table 4. Microscope specifications for live imaging. 
Sample Channel 
 DIC Grey GFP (green) mCherry (red) DAPI (blue) 
pARL2-GFP control 
Exposure time 2ms 1.7s / 31.3ms 
Gain 1x 1x / 1x 
pARL2-GFP/M1 
Exposure time 5.7ms 190.5ms / 24.4ms 
Gain 1x 2x / 1x 
pARL2-GFP/M2 
Exposure time 5.7ms 344.8ms / 12.7ms 
Gain 1x 2x / 1x 
pARL-mCherry control 
Exposure time 3.8ms / 285.7ms 11.4ms 
Gain 1x / 2x 1x 
pARL-mCherry/J 
Exposure time 3.8ms / 344.8ms 11.4ms 
Gain 1x / 2x 1x 
 
2.14.2. Co-localization studies 
The location of the fluorescently labelled protein within the parasite is more accurately 
determined by co-localization studies. This procedure makes use of a labelled antibody 
against a known protein, whose location can be compared to the intrinsic fluorescent 
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protein. For microneme localization, a primary antibody against the well characterized 
micronemal protein EBA-175 was used. The green Alexa Fluor®488 goat anti-mouse 
secondary antibody was used for fluorescent labelling. Antibodies against known rhoptry 
proteins were unfortunately unavailable. 
 
When performing co-localization studies, cells have to be fixed before being made 
permeable for the uptake of antibodies. Erythrocytes were fixed using methods described 
by Tonkin et al. (2004). Two and a half millilitres of whole culture was first pelleted and 
washed with 1ml PBS (1000 x g, 3min, room temperature). Cells were then resuspended in 
1ml of 4% formaldehyde/0.0075% glutaraldehyde and fixed for 30 minutes by constant 
mixing using an intelli-mixer (ELMI Ltd, Latvia) at 12 rpm. Cells were pelleted by 
centrifugation at 3000 x g for 3 minutes at room temperature (Eppendorf Centrifuge 5415 
R, Germany), and washed with 1ml PBS. The pellet was resuspended in 1ml 0.1% Triton 
X-100 and mixed for 10 minutes, to permeablize the cells before they were pelleted and 
washed with 1ml PBS with centrifugation at maximum speed (16100 x g, 3min, room 
temperature). To reduce free aldehydes remaining from the fixing step, the pellet was 
resuspended in 1ml 0.1mg/ml sodium borohydride (NaBH4) and mixed for 10 minutes. 
Cells were washed before resuspension in 1ml 3% BSA in PBS, and mixed for 1 hour. This 
agent blocks globular proteins to prevent non-specific binding to the antibody. The cells 
were pelleted and resuspended in 1ml 1:1000 primary antibody (diluted in 3% BSA in 
PBS) by mixing for 1 hour. The cells were then washed with 1ml PBS three times, with 10 
minutes of mixing for each wash. The secondary antibody was added to a final 
concentration of 5µg/ml (1.25µl diluted in 500µl of 3% BSA), and 2µl of 1:100 diluted 
DAPI was added to the suspension and mixed for 1 hour. Cells were again washed 3 times 
with 1ml PBS and resuspended in 50µl PBS. As per section 2.14.1, some of the cell 
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suspension was mounted for viewing at 63x magnification using the Olympus BX63 
system (table 5).  
 
Table 5. Microscope specifications for co-localization imaging. 
Sample Channel 
 DIC Grey GFP (green) mCherry (red) DAPI (blue) 
3D7 
Exposure time 7.1ms 15.2ms 400ms 7.3ms 
Gain 1x 1x 1x 1x 
pARL-mCherry control 
Exposure time 7.1ms 15.2ms 142.9ms 3ms 
Gain 1x 1x 1x 1x 
pARL-mCherry/J 
Exposure time 7.1ms 15.2ms 400ms 7.3ms 
Gain 1x 1x 1x 1x 
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CHAPTER 3 
RESULTS  
 
3.1. P. falciparum growth rate 
The physiology of the P. falciparum parasite is such that growth in the intraerythrocytic 
life stage is exponential. When culturing these parasites in laboratory conditions, it is 
essential to understand the parasite growth rate in order to keep cultures healthy. The 
parasite growth rate may be accurately determined by flow cytometry. Counts were 
conducted on duplicate Pf3D7 cultures using this method over 4 days (figure 18). Starting 
cultures contained mixed ring and trophozoite stage parasites with very low parasitaemia 
(<1% in both flasks). The low starting parasitaemia contributed to the very small increase 
in growth over the first 24 hours. However, after 48 hours, parasitaemia increased 
approximately four-fold each day as the parasites developed through the 48 hour life cycle 
(figure 18B). Raw cytometric data showed this progression as trophozoites developed into 
schizonts, producing multiple merozoites which infected erythrocytes, producing an 
increase in ring-stage parasites after 24 hours, which developed into trophozoites after 48 
hours, completing the life cycle (figure 18A). These flow cytometry counts showed that 
manual counts were slightly underestimated. Furthermore, these results indicated that 
cultures were well maintained. 
 
 
  
 
 
 
3.2. pARL-mCherry and pARL2
The pARL2-GFP and pARL
allows expression throughout the intra
and JESEBL are both stage
this reason, the crt promoter was
proteins to be expressed in schizonts (Triglia 
 
Figure 18. P. falciparum growth rate measured by flow cytometry. A. Raw flow cytometer data 
showing low levels of rings and trophozoites on day 2, followed by an increase in rings on day 3 as 
trophozoites develop over 24 hours, followed by an exponential increase in parasitaemia after 48 
hours (day 4).  B. Total parasitaemia increased from less than 1% on the 
-GFP vectors  
-mCherry vectors contain the endogenous 
-erythrocytic life stages of P. falciparum
-specific proteins expressed only in the schizont life stage. For 
 exchanged with the ama-1 promoter, which allows the 
et al., 2000, figure 19).  
first day, to 8% on day 4.
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crt promoter which 
. MAEBL 
 
  
 
 
 
3.3. Purification of the ama
Triglia et al. (2000) defined the 
sequence upstream of the 
falciparum 3D7 genomic DNA using primers AMA
 
 
 
 
Figure 19. Vector maps showing pARL
(NotI, AvrII and XhoI) and the dihydrofolate reductase (dhfr) selectable markers are shown for 
both vectors. The region containing the 
region for both vectors. 
-1 promoter 
ama-1 promoter to be contained within the 1455bp 
ama-1 coding sequence. This region was amplified from 
-S and AMA-AS (table 6
-mCherry and pARL2-GFP. Restriction enzyme sites 
crt promoter was exchanged with the 
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P. 
, appendix C).  
ama-1 promoter 
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Table 6. Parameters for primers used to amplify the ama-1 promoter region. 
 Template-specific portion Whole primer  
Name Length (bp) Tm (˚C) Length (bp) Tm (˚C) RE site 
Sense primer 
AMA-S 22 50.1 32 65.4 XhoI 
Antisense primer 
AMA-AS 20 53.6 32 67.2 NotI 
RE- Restriction enzyme 
Tm- Melting temperature, calculated by Integrated DNA Technologies SciTools  
        OligoAnalyzer, 0.25µM oligo, 50mM Na+, 1.5mM Mg++, 1mM dNTP. 
 
 
Two primer annealing temperatures were incorporated into the PCR to allow annealing of 
the template-specific portion, and the whole primer (with added RE sites) to the template 
DNA respectively. PCR parameters were optimized as described below.  
 
The initial reaction was designed to amplify 300ng of template DNA with Go Taq® using 
a gradient of annealing temperatures. The first annealing temperatures used were 40˚C, 
41˚C and 42˚C for 5 cycles, with corresponding second annealing temperatures of 56˚C, 
57˚C and 58˚C respectively, for 30 cycles. The extension temperature was set at 68˚C (due 
to the high AT content) for 2 minutes. Visualization of the products showed only a very 
faint banding pattern, so the PCR was continued for a further 10 cycles using the second 
annealing temperature. The expected size product of 1455bp was absent and only non-
specific amplicons were visualized for each annealing temperature combination (Figure 
20). To optimize, a more diverse primer annealing temperature gradient was used. Both 
200ng and 500ng of template DNA were amplified using an initial annealing temperature 
range of 39.3˚C to 43˚C for 5 cycles and the second annealing temperature set at 58˚C for 
30 cycles. Extension temperature was changed from 68˚C to 64˚C. 
 
  
 
 
As shown in figure 21, the amplification resulted in products of the expected size (1455bp) 
and non-specific amplicons for all reactions employing 200ng template. A concentrated 
amount of template DNA 
amount of contaminants, such as haem,
products were present in reactions employing initial annealing temperatures of 39.3
42.6˚C. Annealing temperatures 
these low temperatures promote non
annealing temperature of 42.6
200ng DNA template were 
 
Figure 20. Amplification of the 
standard. Pf ama-1 amplification products resulting from primer annealing temperature 
combinations of 40˚C and 56˚C (2) 41˚C and 57˚C (3) 42˚C and 58˚C (4). 
     
(500ng) inhibits amplification, probably due to an increased
 remaining from the DNA preparation
below 45˚C are not ideal for amplification by PCR as 
-specific primer annealing. Therefore, the higher 
˚C, an extension temperature of 64˚C and an amount of 
chosen for subsequent reactions. 
ama-1 promoter region shown by agarose gel. 1: DNA size 
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. Strong 
˚C and 
initial 
  
 
 
 
Figure 22 represents the products obtained by duplicate
Enzyme Mix was used to amplify of 200ng of template DNA with anne
42.6˚C and 58˚C for 5 and 30 cycles respectively, and an extension temperature of 64˚C. 
As expected, both reactions show
Figure 21. Optimization of the 
1&16: DNA size standard. Even lanes: Reactions employing 200ng template DNA. Odd lanes: 
Reactions employing 500ng template DNA. Initial primer annealing temperatures are shown, 
while the second annealing temperature was constant at 58
desired 1455bp product amplified with the initial annealing temperature of 42.6
 reactions where High Fidelity PCR 
ed multiple amplicons, including the desired product.
ama-1 promoter region amplification shown by agarose gel. 
˚C. The black arrow indi
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aling temperatures 
 
cates the 
˚C.   
  
 
The Pf ama-1 products amplified with High Fidelity PCR Enzyme Mix were pooled and 
separated on a 0.8% agarose gel at 
extracted and purified in a final volume of 30
of the resulting product was 27ng/
Figure 22. Amplified ama-1
Pf ama-1 products amplified using 
 
80V for 1.5hours. The 1455bp product
µl of nuclease-free water. The concentration 
µl (figure 23).     
 promoter region shown by agarose gel. 1: DNA size standard. 2&3: 
High Fidelity PCR Enzyme Mix. 
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 of interest was 
  
 
3.4. Exchanging the pARL-
The pARL-mCherry plasmid was purified from 
30µl nuclease free water. The
then visualised by gel electrophoresis
 
The linear pARL-mCherry plasmid was digested with 
containing the crt promoter from the plasmid backbone,
were dephosphorylated to
incorporated into the ama-
and XhoI, for directional insertion into the plasmid.
purified and visualised by gel electrophoresis. The concentrat
insert and the 5886bp plasmid backbone were 17.8ng/
24). 
 
Figure 23. Purified Pf ama-1
promoter region. 
 
mCherry crt promoter region with the ama-1
E. coli glycerol stocks in a fi
 plasmid DNA was linearized by digestion with 
, revealing a concentration of 70ng/µ
NotI, to separate the 1493bp region 
 and the resulting ‘sticky ends’ 
 prevent reinsertion of the 1493bp region. The RE sites 
1 promoter region PCR product were also 
 Both the plasmid and the insert were 
ions of the
µl and 50ng/µl respectively (figure 
 promoter region. 1: DNA size standard. 2: 1455bp 
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 promoter region 
nal volume of 
XhoI and 
l.  
digested with NotI 
 ama-1 promoter 
ama-1 
  
 
 
The ligation reaction, which was
and purified pARL-mCherry plasmid (2.3
1 promoter insert (4.8µl). Transformations were successful as bacterial colonies grew on 
the agar plates. However, the negative control also showed colony growth,
much lower level, indicating
the pARL-mCherry plasmid containing the 
were picked from the experimental plate for further analysis.
 
3.4.1. Verification of the pARL
3.4.1.1. Colony PCR 
PCRs were performed using each of the 10 chosen colonies as templates
and AMA-AS primers. An annealing temperature of 58
Figure 24. Agarose gels of digested and purified pARL
1&3: DNA size standard. 2: 
1493bp crt promoter region and 5886bp plasmid backbone.
 
 used for transformation, contained 115ng of the digested 
µl) and 85.4ng of the digested and purified 
 a degree of plasmid recirculization. To identify colonies
ama-1 promoter insert, 10 individual colonies 
 
-mCherry/ama-1 promoter construct 
˚C and an extension temperature of 
-mCherry and ama
Pf ama-1 promoter region (1455bp). 4: pARL
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ama-
 although at a 
 with 
 with the AMA-S 
-1 promoter insert. 
-mCherry with 
 64˚C were employed for 30 cycles. Figure 25
1455bp in size, indicating the presence of the pARL
 
 
 
 
 
3.4.1.2. Restriction enzyme
Plasmid DNA was purified from colony 5 and digested with 
determine banding patterns
three products of 3537bp, 3190bp and 652bp when digested with 
exchanging the promoter region changes the 
products of 4151bp and 3190bp. Digestion of colony 5 plasmid DNA with 
showed the 5886bp plasmid backbone with the 1455bp 
banding patterns strongly suggested that the original pARL
successfully exchanged with the desired 
Figure 25. Colony PCR results of 
plasmid. 1: DNA size standard. 2
expected product of 1455bp is present in all colonies. The s
colony 5 (lane 6) with non-
and 450bp. 
 shows that all colonies produced a product
-mCherry/ama-1 promoter 
 digestion and sequencing 
NotI/XhoI, and 
 (figure 26). The original pARL-mCherry/crt
Xho
XhoI/EcoRI digestion profile to give
ama-1 promoter insert
-mCherry
ama-1 promoter region.
E. coli transformed with the pARL-mCherry/
-11: PCR products amplified from 10 individual colonies. The 
trongest amplicon was produced in 
specific amplicons at approximately 1300bp, 950bp, 800bp, 600bp 
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 of 
plasmid. 
 
XhoI/EcoRI to 
 plasmid showed 
I/EcoRI. However, 
 two 
NotI/XhoI 
. These 
 crt promoter was 
 Sequence results 
ama-1 promoter 
 confirmed the removal of the original 1493bp region and the insertion of the 1455bp 
promoter region in the correct orientation with no mutations
 
 
 
 
 
3.5. Exchanging the pARL2
The 1455bp ama-1 promoter region was excised from pARL
plasmid DNA by digestion with 
inserted into the pARL2-
appendix E). This work was carried out by Alisje Steyn
Medicine and Haematology, the University of the
 
Figure 26. Restriction enzyme digestion of pARL
plasmids. 1&4: DNA size standards. 2: Original pARL
3&6: Engineered pARL-mCherry/
digested with NotI/XhoI.  
 (plasmid map in appendix D
-GFP crt promoter region with the ama-1 promoter region
-mCherry/
NotI and XhoI. The region was then gel purified and 
GFP plasmid as described in section 3.4
, department of Molecular 
 Witwatersrand. 
-mCherry/ama-1 and pARL
-mCherry/crt digested with 
ama-1 digested with XhoI/EcoRI. 5: pARL
75 
ama-1 
).    
 
 
ama-1 promoter 
 (plasmid map in 
-mCherry/crt 
XhoI/EcoRI. 
-mCherry/ama-1 
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3.6. Optimization of large-scale plasmid DNA preparations 
To obtain large amounts of plasmid DNA (250-500µg) from a frozen E. coli glycerol 
stock, the bacteria had to be grown in large volumes. A small amount of the stock must be 
introduced into a small volume starter culture and be allowed to grow and reach 
exponential growth before inoculating a larger culture volume. The volumes of cultures 
and inoculants, and the growth times of starter and large cultures were optimized.  
 
3.6.1. Growth time for starter cultures 
Two pARL-mCherry/ama-1 promoter plasmid glycerol stocks were used to inoculate 5ml 
LB starter cultures. OD600 measurements showed very low growth at 5 hours, with little 
change after 6.5 hours, indicating the lag phase. However, after 8 hours of growth, the 
tested cultures showed OD600 measurements greater than 0.4 (figure 27). According to 
Sezonov et al. (2007), exponential growth is reached at an OD600 of 0.3. Therefore, growth 
was stopped at 8 hours and these cultures were used to inoculate the large volume LB 
cultures. 
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3.6.2. Volumes of large cultures and inoculants 
Starter cultures were used to inoculate volumes of 250ml, 100ml and 5ml LB. Inoculants 
were used at a volume of 1ml or 1/1000 of the larger volume (0.25ml, 0.1ml and 5µl). At 
15 hours, OD600 readings were approximately 2.0 for all cultures and there was very little 
change in readings at 16 and 17 hours (figure 28). These results indicated that the bacteria 
had already reached stationary phase. The 250ml cultures showed better growth than the 
100ml cultures, probably due to better aeration within the larger flasks. Similar growth was 
measured for cultures inoculated with 1ml versus 1/1000 volume.  
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Figure 27. Graph depicting growth rate of E. coli containing pARL-mCherry and pARL-
mCherry/ama-1 plasmids.  
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In conclusion, for optimal large-scale plasmid preparation, 5ml starter cultures were 
allowed to grow for no more than 8 hours, 1ml of the starter culture was used to inoculate a 
larger volume of 250ml and this larger culture was allowed to grow for ~17 hours.     
 
3.7. Generation of chimaeric maebl and jesebl constructs 
To evaluate the role of the CCys domain in trafficking, three P. falciparum chimaeric 
constructs were created from maebl and jesebl coding sequences. The first maebl construct, 
M1, was designed to contain the SP joined to the CCys, TM and CT while the second 
maebl construct, M2, lacked the CCys domain. The third construct, J, was designed to be 
produced from jesebl coding sequence and contained the SP joined to the CCys. The SP 
was included for all constructs to allow for correct trafficking of the chimaeric proteins 
into the ER.  
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Figure 28. Graph showing growth rates of large-scale E. coli cultures containing pARL-
mCherry/ama-1 promoter plasmid. Stationary phase has already been reached at 15 hours.   
 3.7.1. Primer design 
The Pf-MAEBL (PF3D7_1147800.1
SP; two tandem cysteine-rich regions; repeat region; 
Primers were designed to amplify the 174bp SP sequence; the 546bp sequence spanning 
the CCys, TM and CT; and the 207bp sequence spanning 
The sense primer for SP amplification was labelled M
directional cloning into the pARL2
were designed for this domain. Both contained the same template recognition se
however, M-AS2 included an overhanging sequence to allow the SP to be joined to the 
CCys, and M-AS3 included an overhanging sequence to allow joining to the TM. The 
sense primer to amplify the sequence spanning the CCys
S2 and the sense primer to amplify the sequence spanning the TM
M-S3. A single antisense primer, M
sequences. Primer M-AS1 included an 
 
 
 
The protein structure of Pf
tandem DBL cysteine-rich domains, which are characteristic of EBPs, replace the MAEBL 
Figure 29. The maebl and 
Corresponding overlapping primer sequences are shown in green and red. Solid black circles 
represent incorporated restriction enz
) protein consists of six domains: puta
CCys; TM and CT 
the TM and CT only (figure 29
-S1, and included an
-GFP/ama-1 promoter plasmid. Two antisense primers 
-TM-CT region was labelled M
-CT region was labelled 
-AS1, was designed for the amplification of both these 
AvrII RE site for cloning. 
-JESEBL (PF3D7_0102500) is very similar to MAEBL. Two 
jesebl coding sequences. Primers are indicated by arrows. 
yme sites.  
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tive N-terminal 
(Ghai et al., 2002). 
). 
 XhoI RE site for 
quence, 
-
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tandem cysteine-rich regions and the repeat region is absent (Gilberger et al., 2003b). 
Primers were designed to amplify the SP and the CCys (figure 29). The sense and antisense 
primers designed for the amplification of the SP (108bp) were labelled J-S1 and J-AS3 
respectively. As was the case with the MAEBL primers, J-S1 included a XhoI site for 
cloning into the pARL-mCherry/ama-1 promoter plasmid, and J-AS3 contained an 
overhanging sequence to allow the SP to be joined to the CCys. The primer pair designed 
to amplify the CCys (282bp) were designated J-S2 and J-AS4, with an AvrII site included 
on J-AS4. J-AS1 was designed to reverse transcribe jesebl RNA. Primer parameters are 
shown in table 7. Primer sequences are recorded in appendix C. 
 
Table 7. Parameters for primers used to amplify regions of maebl and jesebl. 
Name Template-specific portion Whole primer RE site 
Length (bp) Tm (˚C) Length (bp) Tm (˚C) 
maebl 
Sense primers 
M-S1 27 60.4 37 66.4 XhoI 
M-S2 21 52.2 21 52.2  
M-S3 21 55.9 21 55.9  
Antisense primers 
M-AS1 21 53.1 31 67.5 AvrII 
M-AS2 21/28 52.2/60.4 49 69.4  
M-AS3 21/28 55.9/60.4 49 70.6  
jesebl 
Sense primers 
J-S1 24 56.8 34 68.8 XhoI 
J-S2 27 53.8 27 53.8  
Antisense primers 
J-AS1 23 57.1 33 70.2 AvrII 
J-AS3 27/24 53.8/60.6 51 69.8  
J-AS4 24 53.7 34 66.7 AvrII 
*     Where a forward slash is present, values are for overhanging sequence/template 
        recognition sequence. 
Tm- Melting temperature, calculated by Integrated DNA Technologies SciTools  
        OligoAnalyzer, 0.25µM oligo, 50mM Na+, 1.5mM Mg++, 1mM dNTP. 
  
 3.7.2. P. falciparum RNA isolation and production of cDNA
A 5ml P. falciparum culture was synchronized by two D
apart. Approximately 27 hours post synchronization, when smears showed the presence of 
schizont-stage parasites, RNA was extracted. Schizont
specifically, because maebl 
Spectrophotometric readings sho
reading of 2.11. The sample showed good integrity, as visualized by gel 
with clear products visible for ribosomal RNA subunits and a smear represen
mRNA fraction (figure 30).  
 
 
 
 
RNA was then reverse transcribed in two separate reactions to produce 
single stranded cDNA. For this purpose, the antisense primers M
used to reverse transcribe the whole 
Figure 30. Agarose gel indicating sample integrity of RNA isolated from 
DNA size standard. 2: Pf RNA sample
 
-sorbitol treatments, 48 hours 
-stage parasites were used, 
and jesebl are only transcribed during this stage. 
wed RNA concentration to be 430ng/µl
 
 
-AS1 a
maebl and jesebl mRNA sequences
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, with an A260/A280 
electrophoresis, 
ting the 
maebl and jesebl 
nd J-AS1 were 
. Both of these 
P. falciparum. 1: 
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products were then amplified in PCR reactions employing both sense and antisense primers 
to create double stranded cDNA products.  
 
3.7.3. Amplification of different regions of maebl and jesebl using PCR 
 
Table 8. Primers used to amplify maebl and jesebl domains. 
Primer pair Domain Domain size (bp) Expected PCR product 
size (bp) 
M-S1/M-AS2 maebl SP 1 174 205 
M-S1/M-AS3 maebl SP 2 174 205 
M-S2/M-AS1 maebl CCys-TM-CT 546 556 
M-S3/M-AS1 maebl TM-CT 207 217 
J-S1/J-AS3 jesebl SP 108 145 
J-S2/J-AS4 jesebl CCys 282 292 
 
The 174bp maebl SP was amplified in two reactions using (1) M-S1 and M-AS2 and (2) 
M-S1 and M-AS3 and the 108bp jesebl SP was amplified with J-S1 and J-AS3 (table 8, 
figure 31). The M-S1 primer includes an added 10bp for RE recognition and both M-AS2 
and M-AS3 are extended by 21bp overhangs. The resulting PCR products are therefore 
expected to be 205bp in length. Similarly, additional bases on the J-S1 and J-AS3 primers 
result in an expected length of 145bp for jesebl SP. 
 
  
 
 
The maebl CCys-TM-CT sequence was amplified using M
M-AS1 were used to amplify the 
and 207bp respectively. With the additional 10bp added on to M
the expected products are 556bp and 217bp respectively. Primers J
amplified the jesebl CCys, wi
 
Figure 31. PCR results of amplified 
size standards. 2: maebl SP 1 amplified with M
M-S1 and M-AS3. 5: jesebl 
-S2 and M-AS1, and M
maebl TM-CT sequence. These two sequences are 546bp 
-AS1, for RE recognition, 
th the expected size of 292bp (table 8, figure 32
maebl SP and jesebl SP shown by agarose gel. 1&4: DNA 
-S1 and M-AS2. 3: maebl SP 2 amplified with 
SP amplified with J-S1 and J-AS3.  
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-S3 and 
-S2 and J-AS4 
). 
  
 
 
 
3.7.4. Overlap extension PCR
The maebl and jesebl PCR products were joined together in
create constructs M1, M2 and
and J were 740bp, 401bp and 410bp respectively.
Figure 32. PCR results of amplified 
by agarose gel. 1&4: DNA size standards. 2: 
AS1. 3: maebl TM-CT amplified with M
and J-AS4. 
 
 overlap-
 J as represented in figure 33. The expected sizes of 
 
maebl CCys-TM-CT, maebl TM-CT and
maebl CCys-TM-CT amplified with M
-S3 and M-AS1. 5: jesebl CCys amplified with J
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extension PCRs to 
M1, M2 
 jesebl CCys shown 
-S2 and M-
-S2 
  
 
 
In an overlap extension PCR, the two template sequences are added to a single reaction 
mixture, containing appropriat
resulting product. The components necessary to produce constructs 
listed in table 9.  
 
Figure 33. Schematic representation of overlap ex
M1, M2 and J.  
e primers, which joins and simultaneously amplifies
M1
tension PCR to create chimaeric constructs 
85 
 
 
 the 
, M2 and J are 
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Table 9. Reaction components for production of M1, M2 and J using overlap 
extension PCR. 
Construct M1 M2 J 
Template 1 maebl SP 1 maebl SP 2 jesebl SP 
Template 2 maebl CCys-TM-CT maebl TM-CT jesebl CCys 
Sense primer M-S1 M-S1 J-S1 
Antisense primer M-AS1 M-AS1 J-AS4 
 
Overlap extension PCRs were successful, as amplicons of the expected sizes were obtained 
by agarose gel electrophoresis (figure 34). The amplicon expected for M1 (740bp) was 
clearly visible, however two smaller products of approximately 275bp and 350bp were also 
present. These products are probably due to non-specific binding of the primer pair. PCR 
temperature adjustments were employed in an attempt to eliminate these non-specific 
amplicons, however, these attempts were unsuccessful. The PCR product of interest was 
instead extracted by gel purification. Construct M2 was amplified at the expected size of 
401bp. Very faint non-specific amplicons were observed at 500bp and 700bp, however, the 
very low amounts of these amplicons rendered them insignificant in comparison to the 
fragment of interest. The expected amplicon size of 410bp was produced for construct J 
and a second insignificant non-specific product of approximately 375bp was also present. 
Both M2 and J PCR products were purified before subsequent enzyme digestions. 
 
 
  
 
 
3.8. Insertion of construct J
3.8.1. Ligation and transformation
Both the plasmid (1µg) and insert (500ng) DNA were digested with 
plasmid was dephosphorylated with alkaline phosphatase
map). Digestion of the insert decreases its size from 410bp to 402bp. The plasmid and
insert digestions were then purified and quantified at 49
(figure 35). A ligation reaction was carried out containing ~29ng insert DNA (0.7
~165ng vector DNA (3.4µl) and used to transform 
plates showed four times more growth than control plates. 
the experimental plates and 2 were picked from the control plate for further analysis.  
 
Figure 34. Overlap extension PCR of 
standards. 2: M1 at expected size of 740bp. 3: 
size of 410bp. 
 into pARL-mCherry/ama-1 promoter plasmid 
 
Xho
 (See appendix D
ng/µl and 42
competent E. coli 
Five colonies were picked from 
M1, M2 and J shown by agarose gel. 1&4: DNA size 
M2 at expected size of 401bp. 5:
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I and AvrII and the 
 for plasmid 
 
ng/µl respectively 
µl) and 
cells. Experimental 
 
 J at expected 
  
 
 
 
3.8.2. Analysis of colonies transformed with pARL
3.8.2.1. Colony PCR 
Each of the 7 chosen colonies was amplified
AS4. An annealing temperature of 55
employed for 30 cycles. The expected product (410bp) was present in all
indicating successful transformation.
colonies (figure 36). 
 
Figure 35. Quantification of pARL
electrophoresis. 1: DNA size standard. 2: 
a concentration of 42ng/µl. A non
purified pARL-mCherry plasmid (containing 
a concentration of 49ng/µl.  
 
-mCherry/J 
 using the insert-specific primers J
˚C and an extension temperature of 68˚C were 
 There was no amplification for either of
-mCherry plasmid and construct 
Digested and purified J at expected size of 402bp with 
-specific product is still present at ~375bp. 3: 
ama-1 promoter) at expected size of 7341bp, with 
88 
-S1 and J-
 5 colonies, 
 the control 
J by agarose gel 
Digested and 
  
 
 
 
3.8.2.2. Restriction enzyme
Plasmid DNA was purified from experime
The purified plasmids were digested with 
analysis suggested that both of the colonies had been transformed with the pARL
mCherry/J plasmid as they
1992bp for the HindIII/Hinc
XhoI/AvrII digests (figure 37
2126bp fragment would be decreased to 1736bp in the 
402bp product would be absent from the 
confirmed the insertion of construct
orientation with no mutations.   
 
Figure 36. Colony PCR results of 
DNA size standard. 2-6: PCR products amplified from 5 individual experimental colonies. The 
expected 410bp product is present in all colonies, with the strongest products produced by 
colonies 2, 4&5 (lanes 3, 5&6). 
(lanes 7&8). 
 
 digestion and sequencing 
ntal colonies 2 and 4 (figure 37
XhoI/AvrII and HindIII/Hinc
 showed the expected three products of 3613bp, 2126bp and 
II digests and the expected 7341bp and 402bp product
). If construct J had not been inserted into the plasmid, the 
HindIII/HincII digestions, and the 
XhoI/AvrII digestions. 
 J into the pARL-mCherry plasmid, in the correct 
 
E. coli transformed with the pARL-mCherry/
There was no amplification for either of the control colonies
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, lanes 3 and 5). 
II. This restriction 
-
s for the 
Sequence results 
J plasmid. 1: 
 
  
 
 
3.9. Insertion of constructs 
3.9.1. Ligation and transformation
As per section 3.8.1, both the 
digested, purified and quantified (figure 
concentration was 70ng/µl
39ng/µl. Ligation reactions were
competent E. coli cells.  
 
Table 10. Insert and vector amounts for ligations of inserts M1 and M2 into pARL2
GFP plasmids. 
 
Amount of insert 
Amount of plasmid 
 
Figure 37. RE digestion of pARL
1: DNA size standard. 2&4: Plasmid from colonies 2 and 4 digested with 
Plasmid from colonies 2 and 4 digested with 
M1 and M2 into pARL2-GFP/ama-1 promoter plasmids
 
pARL2-GFP plasmid and M1 and M2 inserts were enzyme
38, see appendix E for plasmid map
, M1 concentration was 24ng/µl and M2 
 carried out as per table 10, and used to transform 
M1 M2 
47ng (2µl) 27ng (0.7µ
154ng (2.2µl) 168ng (2.4µ
-mCherry/J plasmid DNA extracted from transformed 
HindIII/HincII.  
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-
). Plasmid 
concentration was 
-
l) 
l) 
E. coli. 
XhoI/AvrII. 3&5: 
 Transformations using pARL2
growth than control plates. Ten colonies were picked from each of the 
and 2 were picked from the contr
 
 
 
 
3.9.2. Analysis of colonies transformed with pARL2
3.9.2.1. Colony PCR 
Each of the 22 chosen colonies was
M-AS1. Annealing and extension 
For insert M1, eight colonies produced the expected product. The other two colonies gave 
amplified products of unexpected sizes (~390bp and ~300bp). 
similar in size to the non-specific amplicons produced in the 
(figure 34). It is possible that 
the purified sample and then would have transformed 
Figure 38. Quantification of pARL2
electrophoresis. 1: DNA size standard. 2: 
(containing ama-1 promoter)
Digested and purified M1
Digested and purified M2 at expected size of 393bp with a concentration of 39ng/
-GFP/M1 and pARL2-GFP/M2 showed 2
ol plate for further analysis.  
 
-GFP/M1 and pARL2
 amplified using the insert-specific primers M
temperatures of 58˚C and 68˚C were used,
These product
M1 overlap extension PCR 
a small amount of these non-specific products
E. coli, and thus were present in the 
-GFP plasmid and constructs M1 and M2
Digested and purified pARL2
 at expected size of 7343bp, with a concentration of 70ng/
 at expected size of 732bp with a concentration of 24ng/
91 
-3 times more 
experimental plates 
-GFP/M2 
-S1 and 
 for 30 cycles. 
s were very 
 were present in 
 by agarose gel 
-GFP plasmid 
µl. 3: 
µl. 
µl.   
 bacterial colonies. There were nine
~300bp. There was no amplification for either of
 
 
 
 
 
 
3.9.2.2. Restriction enzyme
Plasmid DNA was purified from two
and pARL2-GFP/M2 transformations. The purified plasmids were digested with 
XhoI/AvrII, to excise the inserts,
section 3.8.2.2. Figure 40 
pARL2-GFP/M1 and 7343bp and 393bp for pARL2
the insertions of the M1 and
orientations with no mutations.   
 
Figure 39. Colony PCR results of 
GFP/M2 plasmids. 1,12&23: DNA size standards. 2
individual pARL2-GFP/M1
with the strongest products produced by colonies 1, 6, 9&10 (lanes 2, 7, 10&11). 13
products amplified from 10 individual pARL2
were present in 9 of the 10 colonies. 24&25: Control colonies showing no PCR products. 
 positives for M2, and one unexpected product of 
 the control colonies (figure 39
 digestion and sequencing 
 positive colonies from each of the pARL2
 with results suggesting successful transformation,
shows the expected product sizes of 7343bp and 732bp for 
-GFP/M2. Sequence results confirmed 
 M2 constructs into the pARL2-GFP plasmid
 
E. coli transformed with the pARL2-GFP/
-11: PCR products amplified from 10 
 colonies. The expected product was present in 8 of the 10 colonies, 
-GFP/M2 colonies. Strong expected products 
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-GFP/M1 
 as per 
s, in the correct 
M1 and pARL2-
-22: PCR 
 
  
 
 
 
3.10. Transfection of P. falciparum
3.10.1. Control pARL-mCherry and pARL2
The pARL-mCherry and pARL2
ama-1 promoter, were used in transfections to provide controls for the chimaeric constructs 
M1, M2 and J.  These plasmids 
concentrations of plasmid (>
electroporation times and actual voltage reached for each electroporation pro
recorded in table 11. The electroporation time of 20.1ms, recorded for both of the control 
plasmids, is much higher than the expected time of 12
incorrect salt concentration within the 
therefore prepared for use in subsequent transfection reactions.
 
Figure 40. RE digestion of pARL2
transformed E. coli. 1: DNA size standard. 2&3: Plasmid from 2 pARL2
digested with XhoI/AvrII. 4&5: Plasmid from 2 pARL2
XhoI/AvrII.  
 parasites  
-GFP plasmids 
-GFP plasmids, which had been engineered to contain
were prepared by large-scale plasmid purification
 100µg) are needed for transfection. Plasmid amounts 
-15ms. This was pr
cytomix reaction mixture. Fresh cytomix was 
 
-GFP/M1 and pARL2-GFP/M2 plasmids extracted from 
-GFP/M2 colonies digested with 
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 the 
 as high 
used, 
cedure are 
obably due to an 
-GFP/M1 colonies 
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Table 11. Plasmid amounts, electroporation times and recorded voltages for 
transfections.  
Plasmid Amount used for 
transfection (µg) 
Electroporation 
time (ms) 
Actual voltage (V) 
pARL-mCherry control ~250 20.1 307 
pARL2-GFP control ~100 20.1 309 
pARL-mCherry/J ~300 12.7 309 
pARL2-GFP/M1 ~300 15.9 307 
pARL2-GFP/M2 ~325 12 308 
 
Despite the incorrect salt concentrations of the reactions, the electroporated erythrocytes 
took up both the control pARL-mCherry/ama-1 promoter and the control pARL2-
GFP/ama-1 promoter plasmids. Erythrocytes containing each of the control plasmids were 
infected with P. falciparum parasites and kept under selective WR99210 drug pressure. 
Parasites that have successfully taken up the introduced plasmid will become resistant to 
the drug as the plasmid contains the dhfr gene. Therefore, these parasites will grow under 
constant drug pressure, while those that have not taken up the plasmid will die. pARL-
mCherry and pARL2-GFP transfectants were positive for parasite growth at 25 and 27 
days post transfection, respectively.    
 
3.10.2. Experimental plasmids pARL-mCherry/J, pARL2-GFP/M1 and pARL2-GFP/M2 
As per section 3.10.1, plasmid amounts used, electroporation times and actual voltage 
reached for each electroporation procedure are recorded in table 11. Contrary to the high 
electroporation times recorded for the control plasmids, the times for the experimental 
plasmids pARL-mCherry/J, pARL2-GFP/M1 and pARL2-GFP/M2 were within the 
expected range, at 12.7ms, 15.9ms and 12ms respectively. These results indicated a correct 
salt concentration within each reaction. 
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As was the case with the control plasmids, transfections were successful as cultures were 
positive for parasite growth at 23, 24 and 24 days post transfection for pARL2-GFP/M1, 
pARL-mCherry/J and pARL2-GFP/M2 respectively. 
 
3.11. Transfection verification using PCR 
DNA was extracted from each of the 5 transfected parasite cultures and used in PCRs. This 
was carried out to verify the presence of the introduced plasmid DNA in each of the 
transfectants. Positives controls, employing previously purified plasmid DNA as the 
template, and negative controls, employing DNA extracted from 3D7 P. falciparum 
parasites as the template were included for each PCR. An annealing temperature of 55˚C 
and an extension temperature of 68˚C were used for 30 cycles.  
 
3.11.1. Verification of control pARL-mCherry and pARL2-GFP transfectants 
For the control transfectants, containing pARL-mCherry/ama-1 promoter and pARL2-
GFP/ama-1 promoter, plasmid-specific primers were used. As shown in figure 41, 
amplification of the extracted parasite DNA and the positive plasmid control resulted in the 
expected product of ~530bp for both transfectants, verifying the presence of the plasmids. 
A clear non-specific amplicon of approximately 450bp was also present, among other faint 
non-specific amplicons. The 450bp product was most probably amplified due to non-
specific binding of the forward plasmid-specific primer, as its recognition sequence was 
within the AT-rich ama-1 promoter region. This was also the case when the ama-1 
promoter region was amplified for insertion into the pARL plasmids (figure 22). As 
expected, no amplification took place within the negative controls, only primer dimers 
were present.   
  
 
 
  
 
3.11.2. Verification of pARL2
transfectants 
Plasmid-specific forward primers and insert
reactions. As was the case for the control transfectants, the expected amplicons of 1189bp, 
850bp and 859bp were observed for the pARL2
mCherry/J transfectants and their respect
showed that the plasmids had been
 
Figure 41. PCR of DNA extracted from 
mCherry and pARL2-GFP control plasmids. 1: DNA size standard. 2
pARL2-GFP transfectants (tDNA) and controls (3D7 and purified plasmid). 5
extracted from pARL-mCherry transfectants (tDNA) and cont
(~450bp) and the expected ~530bp products are present in both transfectants and both positive 
controls. Vector maps indicate the positions of the plasmid
GFP-AS & mC-AS).  
-GFP/M1, pARL-GFP/M2 and pARL
-specific reverse primers were used in the PCR 
-GFP/M1, pARL-GFP/
ive positive controls (figure 42
 successfully taken up by the parasites. 
P. falciparum parasites transfected with pARL
-4: DNA extracted from 
rols. Non-
-specific primers used (pARL
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-mCherry/J 
M2 and pARL-
). These results 
 
-
-7: DNA 
specific amplicons 
-S, 
  
 
 
 
 
 
3.12. Visualization of transgenic parasites 
3.12.1. Live imaging 
3.12.1.1. MAEBL chimaeric proteins
Live P. falciparum parasites containing 
pARL2-GFP/M1 construct, the pARL
stained with the blue nuclear stain, DAPI, and visualized by fluorescence microscopy. Late 
schizont stage parasites an
parasites containing no construct
Figure 42. PCR of DNA extracted from 
GFP/M1, pARL2-GFP/M2 
from pARL2-GFP/M1 (tDNA) and controls (3D7 and purified plasmid). 5
from pARL2-GFP/M2 (tDNA) an
(tDNA) and controls. Products of the expected sizes (1189bp, 850bp & 859bp) are present for 
all transfectants and their positive controls respectively. 
 
by fluorescence microscopy 
, M1 and M2 
the pARL2-GFP/ama-1 promoter construct, the 
-GFP/M2 construct, or no construct at all, 
d free merozoites were observed. Unstained control 
 showed no auto-fluorescence under any of the fluorescent 
P. falciparum parasites transfected with pARL2
& pARL-mCherry/J. 1: DNA size standard. 2
d controls. 8-10: DNA extracted from pARL
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-7: DNA extracted 
-mCherry/J 
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filters. DAPI stained control parasites showed blue fluorescence in the nuclear regions, 
with no visible green fluorescence, as expected, indicating the absence of fluorescence 
bleeding (figure 43, top panel). All three transgenic parasite samples showed both blue and 
green fluorescence (figure 43). The parasites expressing the pARL2-GFP/ama-1 promoter 
control construct showed dispersed green fluorescence surrounding and overlapping the 
blue nuclear area, suggesting that the GFP was trapped within the cytosol (figure 43, 
second panel). Parasites expressing the pARL-GFP/M2(CCys) construct showed a 
similar expression pattern to the control (figure 43, third panel), while parasites expressing 
the pARL2-GFP/M1(CCys) construct showed localized green fluorescence separate and 
distinct from the blue nuclear region, with no overlap (figure 43, bottom panel). This 
observation indicated that the GFP-labelled chimaeric M1 protein was properly transported 
from the ER, away from the nuclear region, to the apical end of the merozoites.  
 
The chimaeric M1 (CCys) and M2 (CCys) proteins differed only in the presence or 
absence of the CCys domain. These data, therefore, strongly suggest that the maebl CCys 
domain is essential and sufficient for transporting the protein to the apical secretory 
organelles. Without organelle markers, the exact localization could not be shown, however, 
M1 was presumably localized to the rhoptries as they are the known destination for 
MAEBL.  
  
 
 
 
 
3.12.1.2. JESEBL chimaeric protein
As per section 3.12.1.1., parasites 
construct, the pARL-mCherry/
fluorescence microscopy. Similarly
and no fluorescence bleeding
promoter control construct showed dispersed red
overlapping the blue nuclear area
the cytosol, as expected (figure 44, top pane
chimaeric protein M1 (CCys)
Figure 43. Fluorescence microscopy images of 3D7 parasites, parasites expressing pARL2
GFP/ama-1 promoter (control), pARL2
parasites show no green auto
chimaeric M2 protein show diffuse, overlapping blue and green fluorescence, indicating 
cytoplasmic localization of the GFPs. Parasites expressin
defined blue and green fluorescent regions, indicating apical localization of 
differential interference contrast microscopy.
 J 
containing the pARL-mCherry/ama-
J construct, and no construct at all, were visualized by 
, 3D7 control parasites showed no auto
. The parasites expressing the pARL
 fluorescence surrounding
, suggesting that the mCherry protein was trapped within 
l). A similar result to that
 was expected for chimaeric protein J 
-GFP/M1, or pARL2-GFP/M2. The DAPI stained 3D7 
-fluorescence. The control parasites and parasites expressing 
g the chimaeric M1
 
99 
 
1 promoter control 
-fluorescence 
-mCherry/ama-1 
 and 
 observed for 
(CCys). However, 
-
 protein showed 
M1. DIC: 
 mCherry-labelled protein J
showed dispersed red fluor
spread over the apex of the merozoites 
of chimaeric protein J was 
the protein remained within the cytoso
by the trafficking machinery, but at a lower affinity than 
JESEBL.  
 
 
 
 
 
3.12.2. Co-localization 
Parasites containing the pARL
all were used in co-localization studies. The 
primary antibody against the known protein
secondary antibody. Control 3D7 parasites containing no construct 
Figure 44. Fluorescence microscopy images of parasites expressing pARL
promoter (control) or pARL
fluorescence, indicating cytoplasmic localization of the mCherry protein. Parasites expressing 
chimaeric J protein (red) showed partial overlap with the blue nucle
distribution. DIC: differential interference contrast microscopy. 
 did not show distinct, localized red fluorescence
escence partially overlapping the blue nuclei
(figure 44, bottom panel). This suggests
correctly trafficked to the secretory organelles, while th
l. It is possible that the J CCys domain 
for the endogenous
-mCherry/J construct, the empty plasmid or no construct at 
micronemes were marked green using a 
, EBA-175, and a fluorochrome
-mCherry/J. The control parasites showed diffuse blue and red 
i, as well as apical 
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 and partially 
 that some 
e rest of 
is recognised 
, full-length 
 
-labelled 
showed no auto-
-mCherry/ama-1 
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fluorescence and no fluorescence bleeding. Furthermore, addition of the secondary 
antibody only, showed no non-specific binding (not shown). Control parasites (figure 45, 
top panel) were stained blue with DAPI and green with the EBA-175 marker. As expected, 
no red fluorescence was observed and the merged image showed apical (micronemal) 
localization of EBA-175.  
 
For both the pARL-mCherry/ama-1 promoter line and the pARL-mCherry/J line, there 
was no fluorescence bleeding observed. For control pARL-mCherry/ama-1 promoter 
parasites, the red mCherry protein was dispersed throughout the cytosol and did not co-
localize with the microneme marker (figure 45, middle panel). In the pARL-
mCherry/J(CCys)  line there was co-localization of green EBA-175 and red mCherry 
fluorescence giving a yellow signal, indicating micronemal localization of J (CCys), 
however, distinct green and red proteins were also visible. This indicated that some of the 
J (CCys) protein was correctly transported to the micronemes, while the rest remained 
trapped within the cytosol (figure 45, bottom panel). These results agreed with live 
imaging results.      
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. Protein co-localization fluorescence imaging. 3D7 parasites (top panel) and 
transgenic parasites expressing pARL
mCherry/J(CCys) (bottom panel)
175 (green). The control pARL
fluorescence, indicating cytoplasmic localization of the mCherry protein. Parasites expressing 
chimaeric J (CCys) protein (red) partially overlapped with EBA
-mCherry/ama-1 promoter (middle panel) or pARL
 stained with DAPI (blue) and the micronemal marker EBA
-mCherry/ama-1 parasites showed distinct green and red 
-175 (yellow). 
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CHAPTER 4 
DISCUSSION 
 
The P. falciparum parasite is a complex eukaryotic organism with an extensive proteome 
(Lasonder et al., 2002, Pease et al., 2013). The parasite expresses thousands of proteins 
during the intraerythrocytic life stage which permit host cell invasion and consequent 
development. These proteins have a variety of final destinations both within cellular 
compartments and to extracellular targets such as the PV, the Maurer’s clefts or the host 
cell. The trafficking mechanisms employed to sort these proteins are therefore important 
biological processes. Protein export to the erythrocyte has been well characterized (Marti 
et al., 2004, Deponte et al., 2012). However, transporting mechanisms within cellular 
compartments are still widely unknown. 
 
A significant subset of the P. falciparum proteome is composed of specialized proteins that 
are specifically needed for parasite entry into host erythrocytes. These invasion proteins 
are trafficked to the parasite apical secretory organelles (micronemes and rhoptries), from 
where they are released at the time of invasion. A multitude of invasion proteins are 
produced, allowing the parasite a variety of pathways to enter the host cell. The parasite’s 
ability to switch between pathways renders these invasion proteins poor drug targets 
(Cortes 2008), as evidenced by the fact that many of these proteins have been shown to be 
nonessential by genetic disruptions. However, the mechanisms which allow various 
proteins to be transported to the apical organelles may be common. If this were the case, 
this mechanism may be a potential drug target as it would prevent multiple invasion 
pathways, and it would most probably be parasite-specific.   
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A group of invasion proteins, the DBL-EBP family, possesses an N-terminal cysteine-rich 
DBL domain for recognition of and binding to the erythrocyte surface. These proteins also 
contain a highly conserved C-terminal cysteine rich domain (Adams et al., 2001). This 
CCys, together with the SP and correct timing of expression was found to be necessary and 
sufficient for trafficking of the well known DBL-EBP, EBA-175, to the micronemes 
(Treeck et al., 2006). The conservation of this domain led to the hypothesis that it may be 
involved in trafficking of multiple DBL-EBPs to their apical locations.    
 
4.1. The C-terminal cysteine-rich domain is necessary for trafficking of MAEBL but not 
adequate for trafficking of JESEBL 
Two DBL-EBPs were chosen for evaluation, MAEBL and JESEBL. Chimaeric maebl and 
jesebl constructs were produced and episomally expressed in 3D7 P. falciparum parasites. 
Two chimaera were produced for MAEBL, M1 (CCys) and M2 (CCys) (figure 46). Both 
proteins contained the SP (for transport of the proteins through the ER and Golgi), the TM 
and the CT. The CCys was included in M1 and not in M2. Based on the findings of Treeck 
et al. (2006), it was hypothesized that chimaeric protein M1 would be correctly targeted to 
the secretory organelles and M2 would remain localized within the cytosol, which was 
found to be the case. The finding that M1 was apically localized implies that the protein 
was trafficked to the known destination of the MAEBL protein, the rhoptries. However, 
higher resolution microscopy combined with co-localization studies employing a rhoptry 
marker would confirm the organelle localization of the protein. If both M1 and M2 had 
remained within the cytosol, it would have indicated that other MAEBL domains (the 
tandem DBL domains or the repeat region) were required for correct protein trafficking. If 
both M1 and M2 had been correctly localized, it would have indicated that the common 
domains (TM or CT) contributed to trafficking.   
  
 
 
One construct was produced for JESEBL, construct 
of the JESEBL CCys and the JESEBL SP (figure 47). 
included in the construct as it had
contribute to correct protein trafficking (Treeck 
it was hypothesised in this study 
correct trafficking to the micronemes
localized to the micronemes, the known destination of JESEBL
chimaeric protein remained within the cytoplasmic region while some co
the EBA-175 microneme marker as expected. This indicated that the JES
was sufficient but not completely adequate for trafficking. It is possible that trafficking 
machinery was able to recognise the domain but with low affinity. A domain with a larger 
upstream region than the CCys alone may therefore be necessa
subsequent localization. However, improvements on the resolution of the microscopy 
images generated from the co
protein J is correctly trafficked to the micronemes.
 
Figure 46. Schematic representation of the chimaeric proteins, 
produced from MAEBL.  
J (CCys). This construct was made up 
Only these two domains were 
 already been shown that the cytoplasmic domain did
et al., 2006). Based on their observations, 
that the JESEBL CCys was necessary 
. However, J (CCys) was only par
. A large amount of the 
ry for improved binding and 
-localization study would further discern the extent to which 
 
M1 (CCys)
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 not 
and sufficient for 
tially correctly 
-localized with 
EBL CCys alone 
 and M2 (CCys), 
  
 
4.2. Why are the trafficking requirements different for MAEBL and JESEBL?
4.2.1. Differences in the regions specified as the C
An analysis of the positions of the primers employed by Treeck 
282bp region as the CCys of 
region included 22 amino acids upstream of the first conserved cystein
study, the corresponding 282bp region, based on BLAST sequence alignment, was 
designated as the CCys in 
predicted peptide, was specified for the 
(1992). This domain included 42 amino acids upstream of the initial cysteine residue. 
 
 
Figure 47. Schematic representation of the chimaeric protein 
-terminal cysteine-rich 
et al.
eba-175, encoding a 94aa predicted peptide (figure 48). This 
jesebl. A slightly larger region of 339bp, encoding an 113aa 
maebl CCys, based on prediction
J (CCys), produced from JESEBL. 
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domains 
 (2006) specified a 
e residue. In this 
s by Adams et al. 
 
 
  
 
 
 
 
Sakura et al. (2013) carried out a study with results contradicting those of Treeck 
(2006). The Japanese group showed that the SP and CCys alone were not sufficient for 
microneme trafficking of EBA
conserved cysteine residue, was necessary for correct protein localization (figure 48). An 
arginine residue within this region was essential for trafficking, as replacement of this 
residue with alanine caused the protein to be mislocalized. It was suggested that 
sequence was required in conjunction with the CCys domain for correct protein folding 
and subsequent trafficking. 
 
Figure 48. Trafficking determinants for EBA
The C-terminal cysteine-rich regions (CCys) of EBA
JESEBL and MAEBL (as specified in this study), and the protein sequence necessary for 
trafficking of EBA-175 as specified by Sakura 
upstream region (green), with the essential arginine residue in purple. The eight conserved 
cysteine residues are shown in red.
-175. An extra region of 48aa, 66aa upstream of the first 
 
-175, JESEBL and MAEBL. Sequences shown: 
-175 (specified by Treeck 
et al. (2013), including the CCys and a 48aa 
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Similarly, it is possible that M1 (CCys) was correctly localized to the secretory organelles 
because it included essential information within the 42aa sequence upstream of the first 
conserved cysteine residue (figure 48). However, chimaeric protein J (CCys) was not 
completely trafficked to the micronemes, presumably since it contained only 22aa 
upstream of the first cysteine residue, in contrast to M1. Trafficking machinery may still 
have been able to recognise the cysteine-rich region in J but with low affinity. Additional 
upstream sequence information may therefore be required for proper folding and optimal 
recognition and transport of the protein. 
 
4.2.2. Promoter control of gene expression 
The pARL plasmids used for transfection contained the constitutive crt promoter for 
continuous expression throughout the P. falciparum life cycle. Based on the study by 
Treeck et al. (2006), the crt promoter was replaced with the ama-1 promoter to allow stage 
specific expression of the M1 (CCys), M2 (CCys) and J (CCys) constructs. Although 
the endogenous promoter is always best for precise timing of expression, a promoter with 
an expression profile similar to that of the protein under evaluation is adequate. Two 
different proteins were evaluated in this study, making a single ama-1 promoter 
replacement more efficient than using both the maebl and jesebl endogenous promoters.  
 
Child et al. (2013) proposed that the ama-1 promoter was not sufficient for the correct 
timing of expression of PfSUB2. Transgenic P. falciparum lines were created whereby 
episomal PfSUB2 was expressed under the control of either the ama-1 promoter or the 
Pfsub2 promoter. An indirect immunofluorescence assay showed that trafficking of 
PfSUB2 to the micronemes was incomplete under the ama-1 promoter, while higher levels 
of co-localization with the microneme marker were achieved when PfSUB2 was under 
 control of the endogenous promoter. In a similar way, it is possible that the 
promoter allowed correct timing of expression of construct 
localization, but not for construct 
expression profiles of maebl
similar, indicating that all of these genes should be correctly expressed under the control of 
the ama-1 promoter. Differences in timing of protein expression would likely be due to 
differences in the translation of the different transcripts. 
 
 
 
 
 
 
Figure 49. P. falciparum gene expression profiles for 
The x-axes show each of the parasite developmental stages
late rings (LR), early trophozoites (ER), late trophozoites (LT), early schizonts (ES), late 
schizonts (LS), merozoites (M) and gametocytes (G). The y
percentile relative to all other genes, when parasites are synchronized by 
temperature (Le Roch et al
M1, leading to correct 
J, leading to partial localization. However, the gene 
, jesebl, ama-1, eba-175, and Pfsub2 (figure 49) are very 
 
maebl, jesebl, ama-1, eba
- sporozoites (S), early rings (ER), 
-axes show gene expression a
., 2003, available on PlasmoDB). 
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ama-1 
 
-175 and Pfsub2. 
s a 
sorbitol or 
 4.3. The role of the C-terminal cysteine
Escorter proteins may interact with trafficking machinery via the CCys in order to 
transport MAEBL to the rhoptries and JESEBL to the micronemes. The high
ray crystal structure of the EBA
homodimer whereby the two subunits, consisting of five 
four disulfide bridges (Withers
structure predictions of the JESEBL and MAEBL CCys domains, performed with Phyre2 
(Kelley and Sternberg 2009), confirmed the presence of the same five 
similar folding as the EBA
region among DBL-EBPs indicates that this fold is likely similar for all proteins in the 
family, conferring a conserved function. 
 
 
 
 
 
Figure 50. The crystal structure and the amino acid sequence making up the five 
C-terminal cysteine-rich domain. Crystal structure of EBA
Martinez et al. (2008) (A), MAEB
structures show the N and C termini and the 5 
the five helices. Blue & yellow: residues involved in stabilizing the protein fold, which are 
highly conserved in the DBL
bonds (red lines) (Withers-Martinez 
-rich domain  
-175 CCys domain revealed a novel fold forming a 
α-helices each, are stabilized by 
-Martinez et al., 2008, figure 50). Three
-175 CCys domain (figure 50). The high conservation of this 
 
-175 CCys produced by Withers
L CCys (B) and JESEBL CCys (C) predicted by Phyre2. All 
α-helices. D. Grey: EBA-175 sequence making up 
-EBPs. Red: Conserved cysteine residues connected by disulfide 
et al., 2008).  
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-resolution X-
-dimensional 
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The structure of the EBA-175 CCys domain is conformationally similar to KIX domain of 
the coactivator CREB-binding protein (CBP) (Withers-Martinez et al., 2008), indicating 
the CCys as a potential binding domain with a mechanism similar to that of the KIX 
domain. Furthermore, the KIX domain of CBP can bind two different proteins 
simultaneously (De Guzman et al., 2006). It is therefore possible that the CCys domains of 
MAEBL and JESEBL are responsible for transport to the rhoptries and micronemes 
respectively, by interacting with escorter protein complexes. Other P. falciparum secretory 
proteins are known to be transported in complexes. The rhoptry proteins RAP1, RAP2 and 
RAP3 interact to form a low molecular weight rhoptry complex that is transported via the 
escorter protein RAMA (Topolska et al., 2004, Richard et al., 2009). Furthermore, the high 
molecular weight rhoptry protein complex, consisting of RhopH1, RhopH2 and RhopH3 
may be transported by the same or a similar escorter protein (Ghoneim et al., 2007).  
 
4.4. Hypothetical trafficking models 
MAEBL and JESEBL, like many P. falciparum invasion proteins, possess N-terminal 
signal sequences which direct the newly synthesised proteins through the ER and Golgi. 
Once within the Golgi, MAEBL and JESEBL are most likely sorted and packaged into 
transport vesicles destined for their final destinations, the rhoptries and micronemes, 
respectively (Kats et al., 2008). Treeck et al. (2006) identified the EBA-175 CCys domain 
as the probable recognition site, or ‘sorting signal’ for protein escorters. Because the 
cytoplasmic domain of EBA-175 is not needed for microneme localization (Gilberger et 
al., 2003a, Treeck et al., 2006), these escorters are probably transmembrane proteins 
containing the cytoplasmic signal needed for recognition by trafficking machinery.  
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Many P. falciparum protein-protein interactions have been identified using the yeast two-
hybrid assay (LaCount et al., 2005). Currently, there is no yeast two-hybrid assay data 
available for MAEBL, however, multiple interactions have been found for JESEBL and 
EBA-175 using this system (PlasmoDB, table 12). Unfortunately, these data show no 
common interacting proteins for both JESEBL and EBA-175. Furthermore, none of the 
interacting proteins are likely candidates for trafficking elements. It was, however, 
interesting to note that both the JESEBL and EBA-175 micronemal proteins interact with 
the known rhoptry proteins RhopH2 and RAP, respectively. Additionally, the functions of 
many of the interacting proteins are yet to be defined and other interactions may also be 
found. Therefore, a possible common escorter protein may yet be identified.   
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Table 12. Protein-protein interactions with JESEBL and EBA-175 determined by 
yeast two-hybrid assay (LaCount et al., 2005). 
Proteins interacting with JESEBL 
(PF3D7_0102500) 
Proteins interacting with EBA-175 
(PF3D7_0731500) 
Gene ID Annotation Gene ID Annotation 
PF3D7_0929400 RhopH2 PF3D7_1226500 RAP protein, putative 
PF3D7_1342000 40S Ribosomal protein S6, 
putative 
PF3D7_0903900 60S Ribosomal protein L32, 
putative 
PF3D7_1217200 snoRNA-associated small 
subunit rRNA processing 
protein, putative 
PF3D7_1216900 DNA-binding chaperone, 
putative 
PF3D7_1008400 26S proteasome regulatory 
subunit 4, putative 
PF3D7_0708800 Heat shock protein 110 
PF3D7_0919900 Regulator of chromosome 
condensation, putative 
PF3D7_1035500 Merozoite surface protein 6 
PF3D7_0823300 Histone acetyltransferase 
GCN5 
PF3D7_0102200 Ring-infected erythrocyte 
surface antigen 
PF3D7_1426100 Basic transcription factor 3b, 
putative 
PF3D7_0108700 Secreted ookinete protein, 
putative 
PF3D7_0311100 Pre-mRNA splicing factor, 
putative 
PF3D7_0207600 Serine repeat antigen 5 
PF3D7_0922200 S-adenosylmethionine 
synthetase 
PF3D7_1452400 Conserved Plasmodium 
protein, unknown function 
PF3D7_1410200 Cytidine triphosphate 
synthetase 
PF3D7_1324000 Conserved Plasmodium 
protein, unknown function 
PF3D7_1126700 Conserved Plasmodium 
protein, unknown function 
PF3D7_1312800 Conserved Plasmodium 
protein, unknown function 
PF3D7_1248700 Conserved Plasmodium 
protein, unknown function 
PF3D7_0515400 Conserved Plasmodium 
protein, unknown function 
  PF3D7_1021900 Conserved Plasmodium 
protein, unknown function 
  PF3D7_1249800 Conserved Plasmodium 
protein, unknown function 
  PF3D7_0713900 Conserved Plasmodium 
protein, unknown function 
 
 
Based on past studies and the results from the current study, two models are proposed for 
trafficking of MAEBL and JESEBL to the apical organelles. 
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4.4.1. The ‘escorter’ model 
The results of the current study showed that the highly conserved CCys domain served as 
the recognition site in the partial localization of JESEBL to the micronemes. A 
hypothetical model is represented in figure 51, whereby a common sorting protein 
recognises the CCys domain in EBA-175 and JESEBL and brings the invasion proteins 
into proximity with transmembrane escorter proteins which in turn recruit vesicle coat 
proteins and interact with microneme trafficking machinery such as adaptor complexes and 
clathrin (Kats et al., 2008, Deponte et al., 2012).  
 
Furthermore, the current study indicates the CCys domain as the trafficking determinant 
needed for transporting MAEBL to the rhoptries. Richard et al. (2009) proposed a rhoptry 
targeting model for RAP1 via the glycosylphosphatidyl inositol (GPI)-anchored escorter 
protein RAMA. Based on this model, MAEBL may be packaged into rhoptry-destined 
vesicles by clustering in lipid rafts via an interaction with a GPI-anchored protein. 
Furthermore, interactions between the MAEBL CCys domain and a common sorting 
protein will bring MAEBL into contact with a transmembrane escorter which interacts with 
rhoptry trafficking machinery (figure 51). 
 
  
 
 
 
4.4.2. The ‘bus-stop’ model
Sloves et al. (2012) have shown that simple eukaryotes, such as the apicomplexan 
parasites, contain common trafficking systems for many proteins. It was shown in 
that TgSORTLR is a major cargo receptor that physically interacts with multipl
microneme and rhoptry proteins and guides them through the Golgi, where they can be 
packaged into vesicles. This mechanism may be conserved throughout apicomplexans, as a 
putative sortilin-encoding gene exists in 
 
Figure 51. Hypothetical ‘escorter’ model for the transport of EBA
the secretory organelles. The hypothetical sorting protein (blue oval) is proposed to be common 
for all pathways by interacting with the conserved C
EBA-175, JESEBL & MAEBL.
 
P. falciparum (PF3D7_1451800).    
-175, JESEBL
-terminal cysteine-rich domain present in 
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It is therefore possible that a common escorter protein similar to TgSORTLR is responsible 
for trafficking various microneme and rhoptry proteins to their final destinations 
simultaneously. This hypothesis, represented in figure 52, is supported by the fact that the 
known micronemal proteins, EBA-175 and JESEBL, interact with known rhoptry proteins 
RAP and RhopH2, respectively (table 12). It is hypothesised that the P. falciparum 
SORTLR-type protein binds to both microneme (EBA-175/ JESEBL) and rhoptry 
(MAEBL) proteins within the Golgi lumen, where the complex is packaged into a vesicle. 
The cytoplasmic tail of the PfSORTLR protein then recruits the appropriate apical 
trafficking machinery and vesicular coat components. The microneme and rhoptry proteins 
are then delivered en-route, in a fashion similar to bus-stop terminals. Specific signals at 
each organelle allow the release of the organelle-specific proteins. Thereafter, the vesicular 
coat components and trafficking determinants are recycled for trafficking of the following 
vesicle.  
 
  
 
 
 
4.5. Conclusion 
This study has identified the CCys
DBL-EBP family, to be necessary for trafficking of JESEBL and MAEBL to the 
micronemes and rhoptries, respectively. The 
EBA-175, MAEBL and JESEBL to the secretory organelles may be common for a
EBP invasion proteins. If this were the case, this machinery would be a potential drug 
target. 
 
 
Figure 52. Hypothetical ‘bus
the secretory organelles. The putative 
JESEBL and MAEBL by interacting with the conserved 
permit vesicular trafficking of the proteins to the micronemes and rhoptries.
 domain, which is conserved among members of the 
P. falciparum machinery used for transporting 
-stop’ model for the transport of EBA-175, JESEBL & MAEBL to 
PfSORTLR protein is proposed to bind EBA
C-terminal cysteine
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4.6. Future studies 
Future studies should focus on the identification of the potential common EBA-175, 
JESEBL and MAEBL trafficking determinants. A pull-down assay could be used to 
identify the interaction between the common EBA-175/JESEBL/MAEBL CCys and 
potential escorter proteins. This system has previously been used to identify the interaction 
between RAP1 and the protein escorter RAMA (Richard et al., 2009). Alternatively, a 
novel protein-protein interaction system, which has been used with success, is that of the 
P. falciparum phage display library (Lauterbach et al., 2003 & Lanzillotti and Coetzer, 
2006). The phage display libraries were biopanned against the purified ‘bait’ proteins, 
human erythrocyte spectrin and protein 4.1, and revealed multiple P. falciparum proteins 
with significant binding specificity. This system could be implemented with the purified 
EBA-175, MAEBL or JESEBL CCys domain used as ‘bait’. 
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Appendix A 
 
Commercial chemical reagents 
 
All reagents were stored at room temperature unless otherwise stated. 
 
Acetic acid 17.5M (SMM Instruments, South Africa) 
Agar Bacteriological (Merck, Germany) 
Agarose (SeaKem® LEAgarose) (Lonza, USA) 
Albumax (Gibco, UK) Stored at 4˚C 
Alexa Fluor®488 goat anti-mouse IgG 2mg/ml (Molecular Probes, USA) Stored at 4˚C 
Ampicillin (Roche, Germany) Stored at 4˚C 
Bovine Serum Albumin Fraction V (BSA) (Roche, Germany) Stored at 4˚C 
Calcium Chloride (CaCl2) (Merck, Germany) 
Chloroform (Merck, Germany) 
DAPI 20mg/ml (Sigma, South Africa) Stored at 4˚C 
dNTP mix (10mM) (Inqaba, South Africa) Stored at -20˚C 
D-sorbitol, SigmaUltra (Sigma, South Africa) 
EDTA (Ethylenediaminetetraacetic acid) (Merck, Germany) 
EGTA (Ethyleneglycolbis-aminoethylether-tetra-acetic acid) (BDH, UK) 
Ethanol (BDH, UK) 
Ethidium Bromide (Roche, Germany) 
Formaldehyde solution (HCHO) (Saarchem, South Africa) 
Gentamicin Sulfate (Sigma, South Africa) Stored at 4˚C 
Glucose (C6H12O6) (Saarchem, South Africa) 
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Glutaraldehyde solution (CH2(CH2CHO)2) (Saarchem, South Africa) 
Glycerol (Merck, Germany) 
Hydrochloric acid (HCL) (Merck, Germany) 
Hepes (Sigma, South Africa) 
Hypoxanthine (Sigma, South Africa) 
Magnesium chloride (MgCl2) (Merck, Germany) 
Methanol (Merck, Germany) 
Mouse anti-EBA-175 (Provided by WEHI, Melbourne, Australia) 
Nuclease-free water (Inqaba, South Africa) 
Phenol (Sigma, South Africa) 
Phosphate Buffered Saline (PBS) tablets (Sigma, South Africa) 
Potassium acetate (CH3CO2K) (Saarchem, South Africa) 
Potassium chloride (KCl) (Saarchem, South Africa) 
Potassium dihydrogen phosphate (KH2PO4) (Saarchem, South Africa) 
Potassium hydroxide (KOH) (Sigma-Aldrich, South Africa) 
Potassium phosphate (K2HPO4) (BDH, UK)  
RiboLock (Fermentas, Europe) 
RNase A (Fermentas, Europe) Stored at -20˚C 
RPMI medium 1640 with L-Glutamine and 25mM HEPES (Gibco, UK) Stored at 4˚C 
Saponin (USA, UK) 
Sodium acetate (CH3COONa) (Hopkin & Williams, United Kingdom) 
Sodium bicarbonate (NaHCO3) (Saarchem, South Africa) 
Sodium borohydride (NaBH4) (Saarchem, South Africa)  
Sodium chloride (NaCl) (Saarchem, South Africa) 
Sodium dodecyl sulfate (SDS) (Merck, Germany) 
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di-Sodium hydrogen orthophosphate (Na2HPO4 ·  2H2O) (Saarchem, South Africa) 
Sodium hydroxide (NaOH) (Merck, Germany) 
Thiazole Orange (Sigma-Aldrich, South Africa) 
Trisaminomethane (Tris) (Roche, Germany) 
Triton X-100 (BDH, UK) 
Tryptone (BDH, UK) 
WR99210 (10mM, in DMSO) (provided by Dr Jude M. Przyborski, Marburg, Germany) 
Yeast Extract (Oxoid, UK) 
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Appendix B 
 
Composition of non-commercial reagents 
 
All reagents used were made up with purified water produced by the MilliQTM Water 
System (Millipore Corporation, USA), unless otherwise stated. Heat sterilizations and filter 
sterilizations, where specified, were carried out in a Speedy Autoclave (Gemmy Industrial 
Corp, USA) or using Acrodisc® PF Syringe Filters (Pall Corporation, UK) respectively. 
pH measurements were adjusted using the Beckman® 70 pH meter (Beckman, USA). All 
reagents were stored at room temperature, unless otherwise indicated. 
 
Acetic acid (5M) 
14.3ml concentrated 17.5M acetic acid 
Make up to 50ml with milliQ water 
 
Agar plates 
3g Agar Bacteriological dissolved in 200ml Luria Broth 
Autoclave 
When cooled (<60˚C) add 200µl of 1mg/ml ampicillin 
Pour into plates (±14) and allow to cool 
 
Agarose Gel (1%) 
5g agarose dissolved in 50ml 1X TAE buffer (by microwave heating) 
Allow to cool to 60˚C before adding 2.5µl of 10mg/ml ethidium bromide 
Pour into electrophoresis plate with comb in place and allow to set 
 
Albumax (5%) 
2.5g albumax dissolved in 50ml incomplete medium 
Filter sterilize 
Store at 4˚C 
 
Ampicillin 
1g ampicillin dissolved in 10ml milliQ water 
1ml aliquots stored at -20˚C 
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BSA (3%) 
0.45g BSA 
Make up to 15ml with PBS  
 
Calcium chloride (2M) 
11.1g anhydrous CaCl2 dissolved in 50ml milliQ water 
 
Complete medium [0.5% albumax and 0.2% sodium bicarbonate] 
5 ml 5% albumax 
2.9 ml 3.6% sodium bicarbonate 
Make up to 50 ml with incomplete medium 
Store at 4˚C 
 
Cytomix 
6ml 2M KCl 
7.5µl 2M CaCl2 
1ml 1M potassium phosphate buffer (pH 7.6)
 
10ml 250mM Hepes/ 20mM EGTA 
500µl 1M MgCl2 
Make up to 90ml with milliQ water 
Adjust pH to 7.6 using 1M KOH 
Make up final volume to 100ml with milliQ water 
Filter sterilize 
Store at 4˚C 
 
DAPI (Dilute) 
495µl Incomplete medium 
5µl 20mg/ml DAPI  
 
D-sorbitol (5%) 
5g D-sorbitol dissolved in 100ml milliQ water 
Filter sterilize 
Store at 4˚C 
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EDTA (800mM) 
3g EDTA 
Make up to 85ml with milliQ water 
Adjust pH to 8 with NaOH 
Make up final volume to 100ml with milliQ water 
 
Ethanol (75%) 
75ml 100% Ethanol 
25ml milliQ water 
 
Ethanol (70%) 
70ml 100% Ethanol 
30ml milliQ water 
 
Ethidium bromide  
100mg ethidium bromide dissolved in 10ml milliQ water 
Store at 4˚C 
 
Formaldehyde (4%)/Glutaraldehyde (0.075%) 
600µl formaldehyde solution 
1.13µl glutaraldehyde solution 
Make up to 15ml with PBS 
 
Freezing solution (28% glycerol) 
72ml PBS for freezing 
28ml glycerol 
Filter sterilize  
Store at 4˚C 
 
Glycerol (60%) 
30ml glycerol 
20ml milliQ water 
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Hepes/EGTA (250mM/ 20mM) 
3g Hepes 
0.4g EGTA 
Make up to 40ml with milliQ water 
Adjust pH to 7.6 using 10M KOH 
Make up final volume to 50ml with milliQ water 
 
Hypotonic solution (5mM Potassium phosphate buffer) 
0.22g K2HPO4 dissolved in 200ml milliQ water 
Adjust pH to 7.4 using 1M KH2PO4 
Make up final volume to 250ml with milliQ water 
 
Incomplete medium 
50 mg Gentamicin Sulfate 
50 mg Hypoxanthine 
1 tube RPMI medium 1640 with L-Glutamine and 25mM HEPES (15.89g) 
Make up to 900ml with autoclaved milliQ water 
Mix for at least 1.5 hours 
Adjust pH to 6.72 using 1M NaOH 
Make up final volume to 1L (1kg) with autoclaved milliQ water  
Filter sterilize 
Store at 4˚C 
 
Luria Broth (LB) 
10g tryptone  
10g NaCl  
5g yeast 
25ml of 400mM Tris-HCl (pH 8) [10mM] 
Make up to 1L with milliQ water 
Autoclave  
 
Lysis solution  
500µl stock 0.4M NaOH [0.2M]  
55.6µl 18% SDS [1%]  
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Make up final volume to 1ml with milliQ water 
 
Magnesium chloride (1M) 
10.2g anhydrous MgCl2 dissolved in 50ml milliQ water 
 
Neutralization solution  
1ml 5M stock potassium acetate  
2ml 5M acetic acid 
 
Phenol:Chloroform 
Mix equal volumes of phenol and chloroform 
 
Phosphate Buffered Saline (PBS, pH 7.4) 
Dissolve 1 PBS tablet in 200ml autoclaved milliQ water 
Autoclave  
Store at 4˚C  
 
PBS for freezing 
7.2g NaCl [120mM] 
14.8g Na2HPO4 ·  2H2O [83mM] 
4.4g KH2PO4 [320mM] 
Make up to final volume of 1L with milliQ water 
Store at 4˚C 
 
Potassium acetate (5M) 
245.4g CH3CO2K dissolved in 50ml milliQ water 
 
Potassium chloride (2M) 
7.5g KCl dissolved in 50ml milliQ water 
 
Potassium dihydrogen orthophosphate (1M) 
6.8g KH2PO4 dissolved in 50ml milliQ water 
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Potassium hydroxide (10M) 
5.6g KOH dissolved in 10ml milliQ water 
 
Potassium hydroxide (1M) 
1ml 10M KOH 
9ml milliQ water 
 
Potassium phosphate (1M) 
8.7g K2HPO4 dissolved in 50ml milliQ water 
 
Potassium phosphate buffer (1M, pH 7.6) 
8.7ml 1M K2HPO4 
1.3ml 1M KH2PO4 
 
Re-suspension solution  
0.5g Glucose [50mM] 
0.6ml of stock 800mM EDTA (pH 8) [10mM] 
3.1ml of stock 400mM Tris-HCl (pH 8) [25mM] 
Make up to final volume of 50ml with milliQ water 
 
Saponin (5%) 
0.5g Saponin dissolved in 10ml milliQ water 
 
SDS (18%) 
18g SDS dissolved in 100ml milliQ water 
 
Sodium acetate (3M) 
24.6g CH3COONa 
Add 90ml MilliQ water  
Adjust pH to 5 using acetic acid 
Make up to final volume of 100ml with milliQ water 
 
Sodium bicarbonate (3.6%) 
1.8 g NaHCO3 dissolved in 50 ml autoclaved milliQ water  
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Filter sterilize 
Store at 4˚C 
 
Sodium borohydride (0.1g/ml) 
0.005g NaBH4 
Make up to 50ml with PBS  
 
Sodium chloride (12%) 
12g NaCl dissolved in 100ml milliQ water 
Filter sterilize  
 
Sodium chloride (1.6%) 
1.6g NaCl dissolved in 100ml milliQ water 
Filter sterilize  
 
Sodium chloride/glucose solution 
0.9g NaCl 
0.2g glucose 
Make up to 100ml with milliQ water 
Filter sterilize 
 
Sodium hydroxide (1M)  
1g NaOH dissolved in 50ml milliQ water 
 
Sodium hydroxide (0.4M)  
0.8g NaOH dissolved in 50ml milliQ water 
 
Sorenson’s phosphate buffer (pH 7.2) 
0.42g Na2HPO4 ·  2H2O [47mM] 
0.14g KH2PO4 [20mM] 
Make up to 50ml with milliQ water 
Store at 4˚C 
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TAE (Tris base, acetic acid and EDTA) buffer, pH8 (50X) 
242g Tris [2M] 
5.7ml of 17.5M Acetic Acid [0.1M] 
62.5ml of 800mM EDTA (pH 8) [50mM] 
Add 900ml MilliQ water 
Make up to a final volume of 1000ml with MilliQ water 
 
TAE buffer (1X) 
20ml of 50X TAE Buffer  
980ml MilliQ water 
 
Tris–HCl (400mM) 
4.8g Tris 
Add 85ml MilliQ water 
Adjust pH to 8 using diluted HCl 
Make up to a final volume of 100ml with MilliQ water 
 
Tris EDTA (TE) buffer  
2.5ml 400mM Tris-HCl (pH 8) [0.8 mM]  
0.1ml 800mM EDTA (pH 8) [1 mM] 
Make up to a final volume of 100ml with MilliQ water 
 
Triton X-100 (0.1%) 
15µl Triton X-100 
Make up to 15ml with PBS 
 
WR99210 (10µM) 
1µl 10mM (in DMSO) in 1ml incomplete medium 
Store at 4˚C for 1 month 
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Appendix C 
 
Primer sequences 
 
Red bases indicate the restriction enzyme sites with cleavage site shown by an arrow. Bold 
bases indicate the extra bases added to facilitate enzyme recognition. Overlapping 
sequence bases are shown in blue.   
 
maebl Sense primers 
M-S1 (with XhoI restriction site)  
5’- ATATC  TCGAGATGGGGGTATTGAAACATTTTTTCTTT -3’ 
M-S2 
5’- TCGAATAATAACATGAAAGGA -3’ 
M-S3 
5’- AACATGGTTTATTTTGCTGGA -3’ 
 
maebl Anti-sense primers 
M-AS1 (with AvrII restriction site) 
5’- GCGCC  CTAGGTTTGATTATGTTTTCTTCCGA -3’ 
M-AS2 (with C-terminal cysteine-rich domain overlap) 
5’- TCCTTTCATGTTATTATTCGAAATTTCATATTTGAATTTCCCCTTTCCA -3’ 
M-AS3 (with Transmembrane/ cytoplasmic domain overlap) 
5’- TCCAGCAAAATAAACCATGTTAATTTCATATTTGAATTTCCCCTTTCCA -3’ 
 
jesebl Sense primers 
J-S1 (with XhoI restriction site) 
5’- GCGCC  TCGAGATGAAAGGGAAAATGAATATGTGT -3’ 
J-S2 
5’- CAATATAATAATAGAGATGCTTCTAAA -3’  
 
jesebl Anti-sense primers 
J-AS1 (with AvrII restriction site) 
5’- GCGCC  CTAGGCAAATGTCGTTGTGTCATCATAA -3’ 
J-AS3 (with C-terminal cysteine-rich domain overlap) 
5’- TTTAGAAGCATCTCTATTATTATATTGGGGCCTTTCCTTCAAATACTCTTC -3’ 
J-AS4 (with AvrII restriction site) 
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5’- GCGCC  CTAGGTGTAAATCTTTGTTTTCTAAAACA -3’ 
ama-1 promoter region Sense primer 
AMA-S (with XhoI restriction site)  
5’- GCGCC  TCGAGTTTTGTACAATTTATAACAAGT -3’ 
 
ama-1 promoter region Anti-sense primer 
AMA-AS (with NotI restriction site) 
5’- ATATGC  GGCCGCTTTAAGTATTAATGAGGTGT -3’ 
 
Plasmid-specific primers 
pARL2-GFP and pARL-mCherry Sense primer (pARL-S) 
5’- ACACAAACGTTATACGTACACAGGTT -3’ 
pARL2-GFP Anti-sense primer (GFP-AS) 
5’- CCATCTAATTCAACAAGAATTGGGACAAC -3’ 
pARL-mCherry Anti-sense primer (mC-AS) 
5’- CCTTGAAGCGCATGAACTCCTTGA -3’ 
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